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ABSTRACT 
 
Victor John Weigman Jr. 
HIGH LEVEL INTEGRATION OF GENOMIC DATA FOR IMPROVING 
PREDICTION, PROGNOSTICATION AND CLASSIFICATION OF BREAST 
TUMORS 
Under the direction of Charles M Perou 
 
 The explosion of genomic data has forever transformed the way we approach our 
understanding of diseases and their effect on human systems, shifting the paradigm of 
discovery from paucity of biological data to an overload.  Within a decade our 
understanding of breast cancer has grown from one disease with a few regimented 
treatments to several well-characterized subtypes of well understood pathology and 
clinical significance.    Gene expression microarrays generated an explosion of 
characterization studies that have now generated hundreds of molecular portraits which 
profile specific clinical outcome groups, most of which contain genes strongly associated 
to breast cancer.  Only a few of these gene signatures are robust across datasets, hinting at 
over fitting of selection sets and sample selection bias.  This subjective selection of 
gene/sample pairings was addressed through a novel biclustering method, Large Average 
Submatrices (LAS), by using objective statistical assumptions to recreate robust 
expression signatures.  However, the identification of specific interacting partners and 
downstream events are either rare or unconfirmed in these studies.   
 The identification of Copy Number Aberrations (CNAs) is a vital step in linking 
the addition of genomic health to specific clinical states in these subtypes.  To this effect, 
SWITCH (SupWald Identification of dna copy CHanges), was developed to call CNAs in 
 ii
aCGH platforms and associate them to subtypes.  Subtypes displayed novel CNA 
profiles, most notably in Basal tumors, whose disruptions of key DNA damage response 
genes (BRCA1, WEE1 and RAD-complex genes) were conserved in suitably-paired 
mouse models. 
Identifying pathway states in subtypes is necessary for individualized therapies 
and this work shows the effects of such therapies as well as suggests new pathway 
targets.  Following EGFR inhibition, 90% of Basal tumors showed higher pathway 
activity than other subtypes, which suggest increased sensitivity.  Analysis of conserved 
expression and CNA patterns in C(3)-Tag mice showed an overwhelming activation of 
PI3K-mediated AKT survival in Basal tumors across species a feature of these tumors not 
previously seen.  The work demonstrated here demonstrates how to validate biological 
hypotheses in a genomic era and the power of data integration to highlight biological 
mechanisms that lay hidden under the volumes of modern genomic data. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Breast cancer is the most common type of cancer diagnosed in women 
(accounting for one third) as well as the second leading cause of their mortality by 
cancer, behind lung cancer (ACS 2005).   Incidence rates are affected by race and 
ethnicity, suggesting that varying genetic and environmental influences exist that affects 
breast cancer likelihood.  Breast cancer has become known to be one of multiple diseases, 
much of which has been revealed through genomic analysis of gene expression patterns 
(Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; Sorlie, Tibshirani et al. 2003).  This 
variation has been catalogued using gene expression profiling and genomic DNA copy 
number changes using DNA microarrays, which has resulted in the identification of 
distinct tumor subtypes and improved prognostication.  The long standing goals of my 
thesis have been to use genomic data (gene expression and DNA copy number variation) 
to study human tumors and to identify important disease subtypes, important 
carcinogenetic signaling pathways, and to identify causative genetic events.  
In the genomic era, we have multiple avenues to study the underlying molecular 
biology of these tumors—especially with regards to increasing use of array Comparative 
Genome Hybridization and SNP arrays for measuring the tumor’s inherent genetic 
alterations.   With increasing availability of data from multiple sources, combined with 
biologically-biased analyses, there needs to be statistically rigorous tools that can easily 
be used by everyone.  These goals have required the development of new computational 
tools, and the adaptation of existing algorithms for use on genomic data. Overall, we have 
accomplished these goals and identified new and important insights for breast cancer 
patients. 
 
Breast etiology 
 The epithelial cells of the breast are comprised of multiple dynamic cell types 
which have the ability to proliferate, differentiate, involute and restructure depending on 
a woman’s life stage and level of pregnancy.  Such abilities likely arise from stem cell 
progenitors (Clarke 2005; Woodward, Chen et al. 2005) and settle into 3 main epithelial 
cell types: myoepithelial, basal and luminal.  While myoepithelial cells rarely develop into 
cancers, likely due to their high levels of tumor suppressor genes (TSGs) (Barsky 2003), 
most breast tumors originate from the basal and luminal cells, or at least the bulk of the 
tumor shows these properties while the true tumor initiating cells may be the stem cells.  
Several labs have hypothesized models of breast differentiation.  Keratins 5/6 (K5/6) 
are expressed following growth signals from stem cells into a committed progenitor cell. 
(Figure 1.1).  After this point the potential to differentiate into one of three potential fates 
begins.  A myoepithelial fate is thought to involve increased expression of smooth muscle 
actin (SMA) and p63.  By secreting collagens and laminins into the basement membrane, and 
expressing by intregrins, these cells keep the epithelial cells correctly organized and oriented 
(Gudjonsson, Rønnov-Jessen et al. 2002). From this point the option to develop into cells 
differentiated by expression of estrogen receptor (ER) controls fate as well as introduction of 
K8/18 to the cytoskeleton.  While the more refined luminal cells, with the increased 
expression of GATA3, build the ductal/luminal tissue during pregnancy, the basal-like tissues 
2 
 
arise from the original progenitor cells that lack SMA and p63.  Upon oncogenesis, this gives 
rise to the basal-like tumors as opposed to the more rare, myoepitheliomas (Livasy, Karaca et 
al. 2005). 
 
Gene expression and the subtypes of breast cancer 
By using these cytoskeletal profiles as pathologic markers, we could postulate as 
to the potential cell type of origin of breast tumors, which may be derived from distinct 
stages of epithelial cell development. While these mostly IHC classifications helped 
initial stratification of tumors, it did not show why the same treatment of a similarly-
classified tumor failed to give similar results when given the same therapy.  It was only 
by looking at the transcript profile, through gene expression microarrays, that we first got 
a glimpse of the “molecular portraits” of breast tumors (Perou, Sorlie et al. 2000).   
Utilizing this data, along with the traditional clinical information, identifies groups of 
genes whose expression can segregate patients in clinically informative ways.  In the 
earliest of such, Perou and colleagues found that the expression levels of a handful of 
“intrinsic” genes (those invariable within a group of samples but variable across groups) 
was not only sufficient to recapitulate clinical classifications but predicted patient risk 
groups (Figure 1.2b,c). Not surprisingly, these intrinsic genes also included several genes 
whose protein levels were previously utilized as clinical markers including ER, HER2, 
and the aforementioned keratin genes. The clinical relevance of these intrinsic genes was 
proven to be robust across datasets from different centers and across different microarray 
platforms (Weigelt, Hu et al. 2005; Fan, Oh et al. 2006; Hu, Fan et al. 2006), suggesting 
the utility for microarrays as biomarkers. 
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 Figure 1.1 
Figure 1.1. Model of breast epithelial differentiation. In this model there is a long term repopulating 
stem cell within a stem cell niche. Progressive differentiation can lead to a committed progenitor that is 
positive for keratins 5/6. One possible avenue for further differentiation is to gain expression of keratins 
8/18 and eventual loss of keratin 5/6 expression. The luminal intermediate cell may develop into an ER 
positive cell, an ER negative cell, or an alveolar secretory cell. The luminal cells line the lumen of the milk 
duct and the alveolar cells line the buds at the end of the duct and produce milk. Another avenue for 
differentiation is to gain smooth muscle actin (SMA) and p63 to become a myoepithelial cell that surrounds 
and provides support for the luminal and alveolar cells. Cell images were designed by Jason Herschkowitz 
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 The predictive power of patient-subtype classification has had significant impact on 
outcome prediction (Sorlie, Perou et al. 2001; van 't Veer, Dai et al. 2002; Sotiriou, Neo 
et al. 2003; Ma, Wang et al. 2004) and in recent years had led to real clinical diagnostics 
(OncotypeDx (Paik, Shak et al. 2004), Mammaprint (van't Veer, Paik et al. 2005) and the 
PAM50 assay (Parker, Mullins et al. 2009)).   It is known that these prognostic genes sets 
have explicit functional relevance beyond strong transcriptional correlation but the exact 
manner in which they inter-relate is still under investigation.   
Now there are hundreds of these significant breast cancer gene signatures 
originating from studies performed  across the globe, most of which show strong 
correlation (Fan, Oh et al. 2006), and which can be functionally assessed through 
association to Gene Ontology (Ashburner, Ball et al. 2000) (GO) or pathway 
memberships to characterize biological information.  Hypogeometric mean and Z score 
metrics are typically used to quantify if the number of genes in a particular GO category 
is greater than expected (Dennis, Sherman et al. 2003; Doniger, Salomonis et al. 2003).  
Typically, significant results from these analyses yield broad biological processes such as 
“DNA replication or Metabolism”, which give little more insight than observation of the 
gene names.  Even following the validation of transcript levels downstream targets, 
transcription is merely a reporter of some underlying genomic anomaly which does not 
bring researchers closer to narrowing down oncogenic events. Therefore, my thesis work 
focused not only on transcript levels and patterns, but also on DNA copy number 
analyses, which is a second powerful genomic platform likely to identify cancer causative 
events. 
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Figure 1.2. 
 
Figure 1.2. Expression of intrinsic genes identifies pathologically relevant tumor 
subtypes. A) A heatmap shows the expression of the intrinsic genes and the resultant 
dendrogram based on the hierarchical clustering of the samples.  A colorbar at the bottom 
shows the dynamic range of expression values of the underexpressed in tumor (green) and the 
overexpressed (red) The 3 main subtypes are shown: pink (Her2+), red (Basal) and blue 
(Luminal), with high degree of intra-class correlation.  Lines drawn from the dendrogram 
boundaries link the intrinsic subtypes to those classified by traditional IHC: Her2 (ERBB2-
staining), Luminal (K8/18) and Basal (K5/6).  KM plots showing Overall Survival (B) and 
Relapse Free Survival (C), based on subtypes in A. Adapted from Perou et al. 2000. 
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Clinical Utility of Subtypes 
 The efficacy of drugs to attack a given cancer is strongly dependent on how 
accurately diseases are diagnosed and can be mislead depending on the heterogeneity of 
tumor biopsies.  Building the spectrum of breast cancer subtypes is the first step in the 
better diagnosis of patients and the improved response to therapy.  The presence of ER 
and HER2, along with tumor size, node status and distant metastasis status (TNM) 
govern if a patient receives endocrine therapy, anti-HER2 therapy, and/or chemotherapy.  
The first, Tamoxifen, is an estrogen-like compound which can bind to ER, slowing 
growth, and is given to patients with ER+ (Jordan 2003).  The introduction of aromatase 
inhibitors (which block the production of estrogen) has also shown to improve survival 
for ER+ patients in the long term as well.  For HER2+ patients, trastuzumab is given to 
bind to the ERBB2 extracellular domains and interrupt signaling that would normally lead to 
increased growth and decreased apoptosis (Romond, Perez et al. 2005). Both drugs don’t 
necessarily provide improvement for ER- and HER2- tumors, nor do they always provide a 
permanent improvement for the intended tumors as patients can still succumb to their disease 
while on these therapies.  This still leaves chemotherapy as a viable option and the harsh side 
effects that follow.  Thus there is a great need for more targeted therapies, and we believe 
that a primary means of selecting targets are to focus on disease subtypes and the unique 
targets they express.   
 
Genetic risk factors and commonly mutated genes 
 On the other more discrete end of the analysis spectrum, there are genes whose 
mutations have been associated with increased risk of developing breast cancer.  While 
autosomal recessive germline variants in tumor suppressor genes account for 5-10% of 
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breast cancers, carriers of certain mutations (like BRCA1) predispose patients to specific 
subtypes of disease (Sorlie, Tibshirani et al. 2003).  This has led to many resequencing 
studies of specific genes: BRCA1 and 2 (Thompson and Easton 2004), CHEK2 (Institute 
2005), PIK3CA (Isakoff, Engelman et al. 2005), PTEN (Lynch, Ostermeyer et al. 1997), 
TP53 (Harris and Hollstein 1993) in affected individuals to identify if these genes are 
somatically mutated, or if germline variants exist, within individual patients.  Using this 
information, TP53 mutations have been linked to Basal-like tumors (Sorlie, Perou et al. 
2001) and PIK3CA mutations are found statistically enriched in Luminal-A tumors (Saal, 
Holm et al. 2005).  In cases where mutation data from several studies is present, like in 
the case of PTEN and PIK3CA, mutations were found to be mutually exclusive in breast 
cancer cases (Saal, Holm et al. 2005).  In a recent article, it was found that a specific 
expression signature could predict TP53 mutation status in breast cancer patients 
(Troester 2006).  This suggests that gene mutation likely underlies the subtypes, and that 
in some cases, expression patterns are robust enough to serve as a proxy for the mutation 
status of certain genes.   
 
Copy number aberrations as biomarkers for tumors and normals 
 A well known and observed phenotype of cancer is found in variations in DNA 
copy number usually caused by aberrant replication or disruption of several regions of the 
genome, but only some of which actually contain genes that are correlated to genomic 
instability.  Abnormal function of at least one DNA repair pathway is associated with 
three times greater risk of breast cancer development (Kennedy, Agrawal et al. 2005).  To 
this effect microarrays with chromosomal content were developed, originally with 
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Bacterial Artificial Chromosomes (BACs) and more recently with short oligos that also 
track DNA copy number changes.  These array Comparative Genome Hybridization 
(aCGH) arrays work in a similar fashion to the regular two channel technologies used in 
expression-based platforms and allow simultaneous measurement of tumor and normal 
cell DNA content.  More recently, high-density, Single Nucleotide Polymorphism (SNP) 
arrays have provided a high-throughput method for identifying genome-wide germline 
variation and a means for studying genomic DNA copy number gains and losses with 
increasing resolution (Kennedy, Matsuzaki et al. 2003; Jing Huang 2004).     
 
Identification of CNAs 
 Relative levels of abundance of DNA in samples can be determined in much the 
same way as gene expression through aCGH platforms, but vary in the way they are 
analyzed.  The major difference of which is not just identifying individual probes with 
the most significant differences, but identifying probes that differ significantly from 
probes measuring DNA adjacent to those probes such that discrete regions, or segments 
of DNA, can be identified.  Segmentation analysis was one of the first methods 
developed to identify these breakpoints—the regions where DNA levels differed on 
either side of a given position, segregating probes representing similar copy numbers  
(Olshen, Venkatraman et al. 2004).  This is accomplished by ordering probes based on 
genomic loci, choose a random location and compare the nth quantile of the Z-scores 
created from all probes on either side of the break point to be above a certain threshold.  
To identify the most optimal break-points, this procedure is repeated until the optimal 
scores are identified and several breakpoints are obtained.   
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 While straightforward to understand, this type of approach misses some of the 
underlying biology present in tumors such as: tissue heterogeneity, allele-specific copy 
number and losses or blunts the absolute levels of gain and loss.  While pathologists have 
been able to observe that the tumor tissue sections typically used for experiment aren’t 
always from pure tumor tissue, it’s not been something that was able to be adequately 
quantified.  Utilizing oligonucleotide arrays that measure specific SNPs, we can 
incorporate our understanding of different copy number levels (taken from aCGH) 
combined with what allelic distributions should be observed, which can allow us to make 
estimations of the % contaminating normal tissue in a given sample.  These methods take 
the assumption that normal DNA exists in 2 copies and have associated frequencies of 
homozygous and heterozygous states and that any deviation from these assumptions can 
be used to determine the % normal “contamination” that exists within these samples (Van 
Loo, Nordgard et al.; Sun, Wright et al. 2009).  In a similar manner, the interplay of 
normalized intensity values from these platforms in combination with the reported allele 
frequencies can also be used to identify allele-specific copy gain (i.e. 3 copies of DNA 
can have the following alleles: AAA, AAB, ABB, BBB, whereas 2 copies of DNA can 
have: AA, AB, and BB states).  Using a hidden markov model, which can learn the 
values of all these states, one can determine this ploidy state in a new samples (Wang, Li 
et al. 2007).  This type of analysis can have impact with regards to relating affects of 
these alleles on transcripts, potentially identifying allele specific culprits of oncogenesis. 
 
Specific regions of the genome are altered in breast cancer 
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 With these aCGH arrays, people have been identifying volumes of copy number 
aberrations (CNAs) that give a genetic basis to the observed cancer phenotypes.  One of 
the main findings from these platforms is that some of the changes in DNA copy are non-
random and affect genes with known roles in tumor development.  In some of the earliest 
work using BAC arrays, Richard et al. found early links to ER- tumors: gain in 2p and 6p 
as well as loss in 5q and 12q (Richard, Pacyna Gengelbach et al. 2000).  Following this, 
the gain of 1q and loss of 5q in high-grade (likely Basal-like) tumors has been observed 
in several studies (Iafrate 2004; Loo, Grove et al. 2004; Bergamaschi, Kim et al. 2006; 
Chin, DeVries et al. 2006; Haverty, Fridlyand et al. 2008).  Higher resolution BAC arrays 
and a larger diversity of tumors lead to the identification of high-level genome copy gains 
that were found in common within tumor subtypes (Chin, DeVries et al. 2006).  By using 
cell lines drawn from those tumors, they identified the functional relevance of these 
CNAs (Neve, Chin et al. 2006), in particular they related ESR1, TYK2, FASN, GRB7, 
MEK (S217/219), and MAPK1/3 (Thr202/Tyr204) to Trastuzamab sensitivity.  One 
surprising observation was that of the thousands of genes copy number gains, they only 
saw 66 genes with significant upregulation on the expression level, an observation 
alluded to by others (Pollack, Sørlie et al. 2002; Bergamaschi, Kim et al. 2006; Andre, 
Job et al. 2009); thus a combination of copy number and gene expression analysis can 
limit the list of candidate genes to a more manageable number. 
 While there are some other well-identified events in other subtypes, 1q gain / 16q 
loss in Luminal A tumors and 17q12 gain in Her2 tumors, the Basal-like tumors have the 
largest number of CNAs of any subtype.  This is likely to due to high stage of the tumors 
where, due to DNA repair deficiency resulting in genome instability, many CNA can and 
11 
 
do occur over time.  Bergamaschi identified several CNAs prevalent in Basal-likes: loss 
at 3q12, 4p15-p32, 4q31-q35, 5q11-q31, and 14q22-q23, and gain at 1q12-q41, 6p12-
p25, 7q22-q36, 10p12-p15, 17q25, and 21q22 (Bergamaschi, Kim et al. 2006).  Through 
use of higher-resolution, short-oligo arrays (500K genomic measurements), work done by 
Haverty and colleagues showed additional gains within in 10p14-13, 11q13.3-14.2 and 
20q13.32-33 with frequencies at least 20% in these tumors.  As the arrays improve along 
with the software to identify regions, in parallel with better subtype estimation, it’s likely 
we can better define these regions, identify the causative genes, and possibly use these 
events as biomarkers for drug selection if the target gene is druggable. 
 
Increasing classification accuracy through integration of metadata 
Marcotte (Marcotte, Pellegrini et al. 1999) has stated earliest on the value of 
adding biological evidence to high throughput methods such as expression microarrays.  
Some laboratories have gone further to explain multidimensional frameworks in which 
this can be accomplished (Stephens, Smith et al. 2001; Troyanskaya, Dolinski et al. 2003; 
Lee, Date et al. 2004) but with little explicit results.  This leaves us to build frameworks 
with our comprehensive data that includes genomic, genetic and clinical data on each 
patient, but at increasing complexity.  Recent studies have demonstrated a basal-like 
tumor where data was generated from gene expression, Sanger sequencing, DNA copy, 
and whole-genome shotgun sequencing to not only show several novel features of a 
basal-like tumor but the challenges in utilizing these kinds of data (Ding, Ellis et al.).  
Thus, a computational model and framework for the simultaneous analysis of these 
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dissimilar data types should be more encompassing of the complex biology of breast 
cancer, and thus more likely to lead to personalized care. 
 
Research Introduction 
 It is the basic goal of my thesis work to use the vast volumes of genomic data 
available to learn more about the biology of breast cancers, and to use this information to 
guide therapeutic decision making. The focus of my work has been on the integration of 
multiple data types, and on the development of new analysis methods for genomic and 
genetic data. In the post-genomics era, these tools exist at the boundary of high-
throughput genomic data production and their biological interpretation.  For this purpose 
it is important that their creators understand the difference in causality and correlation, as 
there are plenty of tools that allow investigators to let correlated values inaccurately 
guide interpretation of the data.  In chapter II, we utilized existing cell lines to test for 
subtype-specific drug efficacy and identify what categories of tumors would best respond 
to such therapies.  Chapter III highlights an unbiased method to extract biologically 
meaningful gene/sample relationships from microarray studies, the goal of which is to 
automate the production of biologically relevant, unsupervised gene lists with high 
statistical significance.  Tumor ploidy is addressed in chapter IV, where a new software 
tool can refine the copy number landscape using modern, high-resolution aCGH 
platforms and shows novel subtype-specific CNAs.  In each instance, a better 
understanding of breast tumor subtypes on a molecular level implicates potential 
improved therapy regimens addressing novel oncogenic events. In total, we have 
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advanced our knowledge of breast cancer and provided new tools for future analyses by 
ourselves and others. 
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CHAPTER II 
ROLE OF EGFR SIGNALLING IN BREAST CANCER SUBTYPES 
PREFACE  
 This chapter represents a published paper whose main concept was conceived by 
Katherine Hoadley while I provided analysis design and pathway diagrams with 
integrated expression data.  Throughout the process of this paper, I lead the statistical 
analyses including proper use of significance analysis, including Chi Square tests and 
multiple testing corrections.  I also utilized the representation of gene expression data 
within the context of pathways by using Cytoscape and assisted with constructing the 
pathway and plotting the expression differences within it.  This work represents a 
prototypical  collaborative effort, and I am indebted to Drs. Hoadley and Perou for 
including me in this research 
 
Katherine A. Hoadley, Victor J. Weigman, Cheng Fan, Lynda R. Sawyer, Xiaping 
He,  Melissa A. Troester, Carolyn I. Sartor, Thais Rieger-House, Philip S. 
Bernard, Lisa A. Carey, and Charles M. Perou. EGFR associated expression 
profiles vary with breast tumor subtype.  BMC Genomics. 8:258. 
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ABSTRACT  
 Recent microarray studies have identified distinct subtypes of breast tumors that 
arise from different cell types and that show statistically significant differences in patient 
outcome. To gain insight into these differences, we identified in vitro and in vivo changes 
in gene expression induced by chemotherapeutics. We treated two cell lines derived from 
basal-like epithelium (immortalized human mammary epithelial cells) and two lines 
derived from luminal epithelium (MCF-7 and ZR-75-1) with chemotherapeutics used in 
the treatment of breast cancer and assayed for changes in gene expression using DNA 
microarrays. Treatment doses for doxorubicin and 5-fluorouracil were selected to cause 
comparable cytotoxicity across all four cell lines. The dominant expression response in 
each of the cell lines was a general stress response; however, distinct expression patterns 
were observed. Both cell types induced DNA damage response genes such as p21waf1, but 
the response in the luminal cells showed higher fold changes and included more p53-
regulated genes. Luminal cell lines repressed a large number of cell cycle regulated genes 
and other genes involved in cellular proliferation, whereas the basal-like cell lines did 
not. Instead, the basal-like cell lines repressed genes that were involved in differentiation. 
These in vitro responses were compared with expression responses in breast tumors 
sampled before and after treatment with doxorubicin or 5-fluorouracil /mitomycin C. The 
in vivo data corroborated the cell-type specific responses to chemotherapeutics observed 
in vitro, including the induction of p21waf1. Similarities between in vivo and in vitro 
responses help to identify important response mechanisms to chemotherapeutics. 
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INTRODUCTION  
The epidermal growth factor receptor (EGFR/HER1) is a member of the human 
epidermal growth factor receptor (HER) family of transmembrane receptor tyrosine 
kinases that is linked to growth control, cell adhesion, mobility, and apoptosis (Yarden 
and Sliwkowski 2001). EGFR is an important regulator of epithelial cell biology, but its 
function in breast tumors is complicated by the observation that its function may vary 
according to important clinical features like estrogen receptor (ER) and HER2 status. 
Microarray studies have identified several subtypes of breast cancer arising from at least 
two different epithelial cell types (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; 
Sorlie, Tibshirani et al. 2003; Hu, Troester et al. 2005). Two of the molecular subtypes of 
breast cancer are partly defined by the high expression of ER, while a third is partly 
defined by the genomic DNA amplification and high expression of HER2 (i.e. 
HER2+/ER-, see [5]). The basal-like subtype has low expression of both ER and HER2, 
however, most basal-like tumors highly express EGFR as assessed by both gene and 
protein expression (Nielsen, Hsu et al. 2004).  
High expression of EGFR has been reported in a variety of epithelial tumors 
(Salomon, Brandt et al. 1995), leading to the development of drugs directed against this 
receptor (Baselga 2002; Mass 2004). One of these targeting strategies employs 
monoclonal antibodies (cetuximab) that bind the extracellular ligand-binding domain, 
while other strategies include small molecule inhibitors (gefitinib and erlotinib) that 
compete with ATP for binding to the intracellular tyrosine kinase domain (Culy and 
Faulds 2002; Graham, Muhsin et al. 2004; Dowell, Minna et al. 2005). In non-small cell 
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lung cancer and breast cancer cell lines, it has been shown that some small molecule 
EGFR inhibitors increase cell killing when used in combination with chemotherapeutics 
(Ciardiello, Caputo et al. 2000; Tamura and Fukuoka 2003); therefore, the interactions 
between EGFR inhibitors and cytotoxic agents represent a promising combination for the 
future treatment of epithelial tumors that are dependent upon EGFR-signaling.  
The lack of clinical response in breast cancers treated with gefitinib in vivo has 
been partially attributed to activation of this pathway downstream of EGFR, or 
ineffective methods of identifying those tumors that show an EGFR dependent signature. 
EGF independent activation of the EGFR-pathway via the PI3K/AKT pathway may 
occur through either loss of PTEN or mutation/activation of PI3K, both of which have 
been linked to gefitinib resistance (Moasser, Basso et al. 2001; Bianco, Shin et al. 2003; 
She, Solit et al. 2003). Others have suggested that the MEK/ERK pathway may play a 
more important role in resistance to EGFR inhibitors (Lev, Kim et al. 2004; Janmaat, 
Rodriguez et al. 2006; Normanno, Luca et al. 2006). Recently, Moyano et al. identified 
αB-Crystallin (CRYAB) as a protein that can constitutively activate the MEK/ERK 
pathway in breast epithelial cells and caused a cell line to become EGF independent 
(Moyano, Chen et al. 2006).  
In this study, we hypothesized that the breast tumor "intrinsic" subtypes might 
vary in dependence upon EGFR-signaling, which could be reflective of differences in 
gene expression patterns. Therefore, we used breast cell lines to identify an EGFR-
pathway associated profile and examined interactions between EGFR inhibitors and 
cytotoxic chemotherapeutics in vitro. These analyses identified multiple EGFR-
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associated profiles in vivo that were of prognostic significance, showed important links 
with tumor subtype, and highlight potential downstream activators of the EGFR-RAS-
MEK pathway. 
 
MATERIALS AND METHODS  
Cell culture  
SUM102 and SUM149 cells were a gift from Steve Ethier of Wayne State University 
(Asterand) and represent cell lines derived from ER- and HER2- basal-like breast tumors. 
The SUM cell lines were maintained in an Epithelial Growth Medium developed by the 
Tissue Culture Facility at the University of North Carolina at Chapel Hill (UNCTCF), 
and the SUM149 line was further supplemented with 5% FBS. The MCF-7, ZR-75-1, 
HME-CC and ME16C cell lines were obtained and maintained as previously described 
(Troester, Hoadley et al. 2004; Troester, Hoadley et al. 2004).  
 
Cytotoxicity assay  
Cell line sensitivities to drugs were assessed using a mitochondrial dye conversion assay 
(MTT, Cell Titer 96, Promega, Madison, WI) as described previously with the following 
modifications (Troester, Hoadley et al. 2004). Cells were seeded into triplicate 96-well 
plates (SUM102, HME-CC, and ME16C – 5,000 cells/well, SUM149 – 10,000 cells/well, 
MCF-7 and ZR-75-1 – 7,000 cells/well) and allowed to adhere overnight. Cells were 
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treated for 72 h with a range of doses of individual drugs. Carboplatin, doxorubicin, 5-
fluorouracil, paclitaxel, and LY294002 were purchased from Sigma (St. Louis, MO). 
Gefitinib was a gift from Astra- Zeneca and cetuximab was purchased from the UNC 
Hospitals Pharmacy Storeroom (Chapel Hill, NC). U0126 was purchased from Cell 
Signaling (Danvers, MA). The inhibitory concentration that caused a 50% reduction in 
MTT dye conversion (IC50) dose was determined as previously described (Troester, 
Hoadley et al. 2004).  
Drug combination interactions were analyzed using methods developed by Chou 
and Talalay (Chou and Talalay 1984). Using cell lines plated as described above, seven 
treatment combinations consisting of constant ratios of IC50 doses (ranging from one-
eighth of each dose to eight times the IC50) were applied to cells and growth compared to 
untreated controls using the MTT assay. Four treatment schedules were tested: 72 h 
concurrent, 72 h inhibitor followed by 72 h chemotherapeutic, 72 h chemotherapeutic 
followed by 72 h inhibitor, and a 144 h concurrent dose with a media change at 72 h 
(similar to the sequential treatments). CalcuSyn (BioSoft, Cambridge, UK) was used to 
determine the combination index, which is a measurement of the type of drug 
interactions. A combination index (CI) of one indicates an additive response, less than 
one indicates a synergistic response (greater than additive), and greater than one indicates 
an antagonistic response (less than additive).  
 
Collection of mRNA for cell line experiments  
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For each treatment, the SUM102 cells were grown in 15- cm dishes until 50–60% 
confluence. SUM102 cells were treated for 48 h with a dose equivalent to two times the 
72h-IC50 dose of each inhibitor (treated samples). To identify EGFR, MEK, and PI3K 
activation signatures, the medium was removed after 48 h of inhibitor treatment and 
replaced with fresh medium without inhibitor. mRNA was harvested at 4 h, 8 h, and 24 h 
(post treatment samples). Cells were harvested by scraping, quickly placed into RNA 
lysis buffer, and mRNA was isolated using the Micro-FastTrack kit (Invitrogen, 
Carlsbad, CA).  
 
Collection of RNA for human tumor samples 
 248 breast tissue samples represented by 241 fresh frozen breast tumor samples and 7 
normal breast tissue samples were obtained from four different sources using IRB 
approved protocols from each participating institution: the University of North Carolina 
at Chapel Hill, The University of Utah, Thomas Jefferson University and the University 
of Chicago; many of these samples have appeared in previous publications (Weigelt, Hu 
et al. 2005; Hu, Fan et al. 2006; Oh, Troester et al. 2006; Perreard, Fan et al. 2006), and 
117 are new to this study. The patients were heterogeneously treated in accordance with 
the standard of care dictated by their disease stage, ER, and HER2 status.  
 
Tumor sequence analysis 
  
26
 Tumor genomic DNA samples were isolated from 96 tumors using Qiagen (Valencia, 
CA) DNAeasy Kits according to the manufacturer’s protocol. Gene sequencing analyses 
were performed at Polymorphic DNA Technologies (Alameda, CA) using an ABI 3730xl 
DNA sequencer and cycle sequencing, according to the manufacturers protocol. A two-
step "boost/nested" PCR strategy was used where first a PCR reaction is performed to 
generate a larger DNA fragment, which is then used as a template for the nested reaction 
with a second set of PCR primers. Double stranded sequencing was performed on the 
nested product using the nested PCR primers as the sequencing primers. Exons 19 and 21 
of EGFR were sequenced across all 96 patients, while exons 1 and 2 of KRAS2, 1 and 2 
of HRAS, and 11 and 15 of BRAF were sequenced across 54 patients. No somatic 
alterations were detected.  
 
Microarray experiments 
 For the human tumor samples, the total RNA isolation and microarray protocols were 
performed as described in Hu et al. (Hu, Troester et al. 2005); in this study, a number of 
tumor samples from previous studies were retested using a new custom Agilent 
microarray enriched for breast cancer genes. For cell lines experiments, labeled cRNA 
was generated from the mRNA using Agilent's Low RNA Input Linear Amplification Kit 
as described in Hu et al. (Hu, Troester et al. 2005). For the cell line studies, the 48 h 
inhibitor treated samples were compared to an untreated cell line reference to look for 
effects of an inhibitor, and for the post treatment samples, to identify an activation 
signature for that drug/pathway. Labeled experimental sample (Cy5 CTP) and reference 
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(Cy3 CTP) were mixed and co-hybridized overnight on the same Custom 22K Agilent 
Human Whole Genome Oligonucleotide Microarray described above. Two to four 
microarrays per experimental cell line condition were performed, including a dye-flip 
replicate for gefitinib- and cetuximab treated samples. Microarrays were scanned on an 
Axon GenePix 4000B microarray scanner and analyzed using GenePix Pro 5.1 software. 
Microarray raw data were uploaded into the UNC Microarray Database and Lowess 
normalization was performed on the Cy3 and Cy5 channels. The microarray and patient 
clinical data are available at UNC Microarray Database (UNCUMD) and have been 
deposited in the Gene Expression Omnibus under the accession number GSE6128.  
 
Statistical analyses 
 Intra-class correlations between cell line microarray experiments were performed to 
judge the degree of concordance between experiments/samples as described in Hu et al. 
(Hu, Troester et al. 2005). Unsupervised analyses of the cell line samples were performed 
by selecting genes with an absolute signal intensity of at least 30 units (our cutoff for 
background signal intensity) in both channels in at least 70% of the samples tested and 
that also showed a Log2 R/G Lowess normalized ratio of two on at least two arrays. The 
program Cluster was used to hierarchically cluster samples and genes, and Treeview was 
used to view the data (Eisen, Spellman et al. 1998; Eisen and Brown 1999). Using the 
SUM102 treated cells, a one-class Significance Analysis of Microarrays (SAM) was used 
to identify significantly induced genes in all the post treatment experiments (two to three 
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arrays for each experimental time point) (Tusher, Tibshirani et al. 2001). Gene ontology 
enrichment was assessed using EASE (Hosack, Dennis Jr et al. 2003).  
Analyses of the primary tumor data used the top 500 induced genes from the cell 
line SAM analysis described above, after filtering for 30 units in both channels in at least 
70% of the tumor samples. These genes were examined in a two-way hierarchical 
clustering analysis with the 248 UNC tumor sample set. Three distinct expression 
patterns were observed and labeled as Clusters #1–3. Next, the genes in each of these 
three tumor-defined clusters were identified in the NKI295 patient data set (Chang, 
Nuyten et al. 2005; van't Veer, Paik et al. 2005), and a mean expression value for each 
cluster for each patient was determined. The NKI295 patients were then rank-ordered and 
separated into (a) two equal groups representing low and high, or (b) three equal groups 
representing low, medium, and high average expression for each cluster. In addition, 
similar gene-based rank order patient stratifications were performed for individual genes 
that included EGFR, HER2, HER4, EGF, TGFA, AREG, CRYAB, KRAS, KRAS-amplicon 
profile, HRAS, NRAS, PIK3CA, PIK3R1, AKT1, AKT2, AKT3, MEK1, MEK2, ERK1, and 
ERK2. Survival analyses were performed using Cox-Mantel log-rank test in Winstat for 
Excel (R. Fitch Software). Multivariate Cox proportional hazards analysis was performed 
in SAS v9.0 (SAS Statistical Software, Cary, NC) to estimate the hazard ratio associated 
with cluster expression in the three groups after controlling for standard clinical 
predictors (age, ER status, size, grade, and node status). Chi Square tests (SAS v9.0) were 
used to examine associations between cluster groups, individual genes, and tumor 
subtype.  
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Gene expression relative levels were visualized in relation to the EGFR signaling 
pathway using Cytoscape (Cytoscape; Shannon, Markiel et al. 2003). The pathway was 
built de novo based on information from KEGG(KEGG; Ogata, Goto et al. 1999), 
BioCarta (BioCarta), and a review by Yarden and Silowkoski (Yarden and Sliwkowski 
2001) with a focus on the RAS-MEK and PI3K/ AKT components. Using the 248 UNC 
breast tumor microarray dataset, an average gene expression profile is displayed for the 
Luminal A, Luminal B, basal-like, and HER2+/ER- tumors. Tumor "intrinsic" subtype 
was determined for each sample using the 306 gene Centroid Predictor described in Hu et 
al. (Hu, Fan et al. 2006); the subtype classifications used for the NKI295 sample set were 
also derived from this same centroid predictor and are described in Fan et al. (Fan, Oh et 
al. 2006).    
 
RESULTS   
Cell line models of breast cancer 
 Breast cancer is a heterogeneous disease arising from at least two distinct epithelial cell 
populations, therefore, we selected cell line models of basal-like and luminal cells to 
begin our investigations of the EGFR-pathway. The MCF- 7 and ZR-75-1 cell lines were 
derived from breast tumors of luminal origin and have expression of CK8/18 and ER. 
Our previous studies examining cell lines of basal-like origin used immortalized human 
mammary epithelial cell lines (HMECs) (Troester, Hoadley et al. 2004; Troester, 
Hoadley et al. 2004); however, these lines are derived from normal rather than tumor 
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tissue. Two ER-negative and HER2-non-amplified tumor-derived cell lines, SUM149 and 
SUM102, have been previously shown to express EGFR (Sartor, Dziubinski et al. 1997; 
Lev, Kim et al. 2004) and show basal-like expression profiles (Bertucci, Finetti et al. 
2005). The SUM102 and SUM149 lines share many characteristics with the basal-like 
tumors including expression of CK5/6; therefore, we included these two tumor-derived 
lines as in vitro models of basal-like breast cancers. By microarray analysis, EGFR gene 
expression was low in the luminal cell lines and higher in the basal-like lines. EGFR 
protein expression by Western blot analysis was detectable in the basal-like lines, but not 
in the luminal lines (data not shown).  
 
Drug sensitivity assays 
To assess EGFR inhibitor sensitivity, the six cell lines described above were 
treated for 72 h with a range of doses of gefitinib or cetuximab and a MTT assay was 
used to determine IC50 doses (Table 2.1). In response to gefitinib, the basal-like tumor-
derived cell lines (SUM149 and SUM102) were two- to 100-fold more sensitive than the 
luminal lines. The two immortalized HMEC lines were 33- and 50-fold more sensitive to 
gefitinib than the luminal lines, suggesting that the basal-like cell lines as a whole were 
more sensitive to gefitinib versus the luminal cell lines. Cetuximab sensitivity was 
observed in only a single cell line (SUM102, IC50 = 2 ug/ml), with IC50 doses for MCF-
7, ZR-75-1, SUM149, ME16C2, and HMECC not achievable even with cetuximab doses 
as high as 100 ug/ml. These cell lines were also treated with inhibitors that affect targets 
downstream of EGFR in the pathway including U1026 (MEK1/2 inhibitor) and 
LY294002 (PI3K inhibitor). Most of the cell lines had a similar level of sensitivity to 
U0126 with the exception that SUM102 was approximately 5-fold more sensitive. IC50 
doses for LY294002 were similar for most lines with the exception of ME16C and 
SUM149 cells, which were approximately 5-fold more resistant than the other lines. The 
SUM102 line was the only cell line that was sensitive to all four inhibitors and has 
previously been shown to be EGFR-dependent (Sartor, Dziubinski et al. 1997), and thus, 
was chosen for further analyses of the EGFR pathway.  
 
Table 2.1 
Table 2.1: Estimated IC50 doses of breast cell lines treated with EGFR, MEK, and PI3K 
inhibitors 
 
Drug combination analyses 
Given the observation that most biologically targeted drugs like cetuximab 
typically show low response rates when tested in vivo alone, we examined the effects of 
chemotherapeutics (carboplatin, doxorubicin, 5-fluorouracil, and paclitaxel) as single 
agents across all cell lines and the combination of cetuximab plus chemotherapeutics in 
SUM102 cells. Note, we only used the SUM102 cells for the combination studies 
because they were the only cell line tested for which an IC50 dose for single agent 
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cetuximab could be obtained. We also tested the combined effects of gefitinib, U0126, 
and LY294002 with chemotherapeutic agents in SUM102 cells. First, individual drug 
sensitivity (IC50 doses) for each chemotherapeutic was determined for all six cell lines 
(Table 2.2). The relative sensitivities varied across the cell lines and did not appear to 
correlate with cell type (i.e. basal-like vs. luminal), with the exception that the two basal-
like tumor-derived cell lines (SUM102 and SUM149) were at least three-fold more 
sensitive to carboplatin, and at least twofold more resistant to 5-fluorouracil when 
compared to their immortalized HMEC counterparts or the luminal cell lines.  
 
Table 2.2 
Table 2.2: Estimated IC50 doses of breast cell lines treated with chemotherapeutics 
 
As a starting point for combination experiments, we treated SUM102 cells for 72 h with 
cetuximab and a chemotherapeutic simultaneously. Synergistic interactions were not 
evident in any combination and all combinations were antagonistic as assessed by the 
method of Chou and Talalay in CalcuSyn (Chou and Talalay 1984) (Figure 2.1). We next 
analyzed the effect of sequential treatment: cells were treated for (a) 72 h with cetuximab 
followed by 72 h with chemotherapy, (b) 72 h with chemotherapy followed by 72 h with 
cetuximab, or (c) with cetuximab and chemotherapy simultaneously for 144 h. 
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Chemotherapy followed by cetuximab was generally more growth inhibitory than 
cetuximab followed by chemotherapy (Figure 2.1). The one exception was cetuximab 
with paclitaxel, where all sequence combinations were antagonistic (Figure 2.1). 
However, this antagonism may result from the high sensitivity to paclitaxel already 
observed in the SUM102 line (Table 2.2). Carboplatin followed by cetuximab and the 
144 h concurrent treatments were synergistic even at low doses of both drugs. 5-
fluorouracil followed a similar trend to that of carboplatin, while in the doxorubicin 
combinations synergy was only evident at doses higher than the IC50 dose for 
doxorubicin first, or the 144 h concurrent (Figure 2.1). Similar results were observed for 
combinations with gefitinib and LY294002 (a PI3K inhibitor) where chemotherapy 
followed by each inhibitor, and the 144 h concurrent treatments, were more effective than 
the biological inhibitor first (data not shown). Synergy was also observed in SUM149 in 
addition to SUM102 for combinations of gefitinib and carboplatin. U0126 (a MEK 
inhibitor) combinations exhibited different results and chemotherapeutics given first 
followed by U0126 were slightly less synergistic than the U0126 first or concurrent 
treatment; however, for U0126, all combinations except doxorubicin first, or paclitaxel 
first, were synergistic (data not shown).  
 
EGFR-associated gene expression patterns in vitro 
To identify an EGFR-pathway associated profile, we analyzed the gene expression data 
of the SUM102 cell line treated with EGFR inhibitors (baseline) and then released from 
this inhibition to identify those genes that were induced upon removal of the inhibitor. 
  
Figure 2.1 
Figure 2.1. Effects of different combination schedules of cetuximab with chemotherapeutics in 
SUM102 cells. Cells were treated with four different combination schedules: 1) 72 h cetuximab followed 
by 72 h chemotherapy, 2) 72 h chemotherapy followed by 72 h cetuximab, 3) 72 h concurrent 
chemotherapy and cetuximab, and 4) 144 h concurrent chemotherapy and cetuximab. A) Growth inhibitory 
effects of cetuximab and carboplatin combinations. B) Combination analysis of cetuximab and carboplatin 
treatments. C) Growth inhibitory effects of cetuximab and paclitaxel combinations. D) Combination 
analysis of cetuximab and paclitaxel treatments. E) Growth inhibitory effects of cetuximab and 5-
fluorouracil combinations. F) Combination analysis of cetuximab and 5-fluorouracil treatments. G) Growth 
inhibitory effects of cetuximab and doxorubicin combinations. H) Combination analysis of cetuximab and 
doxorubicin treatments. Combination Index (CI) values below one are synergistic, equal to one are additive 
and greater than one are antagonistic. 
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Using an unsupervised analysis, we hierarchically clustered all time points from the 
cetuximab and gefitinib treatment experiments and identified over 500 genes that 
changed in expression at least 4-fold (Figure 2.2). 
 Even though the two EGFR inhibitors have different mechanisms of inhibition, 
SUM102 cells treated for 48 h with gefitinib or cetuximab showed very similar gene 
expression patterns. Intra-class correlation (ICC) values between the gefitinib and 
cetuximab treated samples ranged from 0.627 to 0.934, and this level of similarity is 
evident in the short dendrogram branches from the cluster analysis (Figure 2.2B). The 
post treatment samples (i.e. after removal of inhibitor) that represent the reactivation of 
the EGFR-pathway were even more similar (ICC within each time point ranged from 
0.862 to 0.962). A two-class SAM analysis to look for differences between gefitinib-post 
treatment samples versus cetuximab-post treatment samples identified only 58 
significantly different genes with a false discovery rate (FDR) of 5%; thus, from a 
transcription standpoint, gefitinib and cetuximab elicited very similar results in SUM102 
cells.  
In response to gefitinib and cetuximab, the SUM102 cell line exhibited decreased 
expression of many proliferation genes (Figure 2.2). There was also a large cluster of 
genes that were induced by the inhibitors, consisting predominately of hypothetical genes 
with unknown functions. We were more interested in the genes induced after the removal 
of the inhibitor as this reflects the gene expression patterns associated with the 
reactivation of the EGFR pathway. As early as 4 h and 8 h after inhibitor removal there 
was a substantial increase in expression for two ligands of EGFR, namely amphiregulin 
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and epiregulin. Cyclin A1 was also substantially increased (Figure 2.2C and 2.2D). 
Starting at 4 h and continuing through 8 h and 24 h, genes with known roles in G1/S 
phase such as CDC6, CDC7, TIMELESS, and ORCL6 were increased (Figure 2.2E). By 8 
h and 24 h, DNA synthesis and DNA damage checkpoint genes were induced (Figure 
2.2F). Classical gene expression-defined proliferation genes including STK6 and Cyclin 
B1 were highly induced by 24h (Figure 2.2G). There was also a repression of negative 
regulators of growth such as Growth arrest-specific 1 and Cyclin G2.  
 
Role of MEK and PI3K in the in vitro EGFR-profile 
Activation of EGFR leads to the downstream activation of other signaling 
components including the MEK/ERK and PIK3/AKT pathways (Yarden and Sliwkowski 
2001). To examine the role of these effectors, we treated the SUM102 cell line with the 
MEK1/ 2 inhibitor U0126 and the PI3K inhibitor LY294002 alone, and in combination. 
Microarray time course experiments using inhibitor treated cells followed by inhibitor 
removal were conducted for U0126 and LY294002 similar what was done for the 
cetuximab and gefitinib experiments. The observed gene expression profiles for the 
U0126 and the LY294002 experiments were similar in both gene identity and direction 
when compared to the cetuximab/gefitinib profile, but gene expression changes were 
typically reduced in magnitude. The U0126 and LY294002 signatures when compared to 
each other were very similar at the 4 h and 8 h time points (average ICC = 0.83), but 
diverged at 24 h post treatment (average ICC = 0.59). The gene expression signatures of 
LY294002 and U0126 samples were also correlated with the gefitinib/ cetuximab gene 
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expression patterns at 4 h and 8 h post treatment (LY294002 compared to 
gefitinib/cetuximab ICC = 0.83, U0126 compared to gefitinib/cetuximab ICC = 0.77). 
The LY294002 and U0126 24 h post treatment samples were less correlated with 
gefitinib/cetuximab 24 h post samples (LY294002 compared to gefitinib/cetuximab ICC 
= 0.51, U0126 compared to gefitinib/cetuximab ICC = 0.41). We also treated cells with 
LY294002 and U0126 simultaneously to determine if the combined treatment would 
more completely recapitulate the EGFR-associated profile; the 24 h post combined 
treatment samples showed a higher correlation value to the gefitinib/ cetuximab samples 
(average ICC = 0.73), but still did not account for the entire gene expression pattern of 
the 24 h post cetuximab/gefitinib treatments. These results suggest that the 
cetuximab/gefitinib profile could not be simply attributed to either the MEK or PIK3 
pathway, but that the combination of these two pathways was more representative of the 
EGFR-signature than either pathway alone.  
 
EGFR-associated gene expression patterns in vivo  
To identify an EGFR-associated in vivo signature, a one-class SAM analysis was 
performed using the SUM102 cells to identify the genes that were statistically induced in 
the post treatment samples relative to the inhibitor treated samples. Adjusting the SAM 
delta value to obtain the largest gene set with less than 5% FDR resulted in a gene list 
that was extremely large (10,017 genes, 4.97% FDR), therefore, the top 500 induced 
genes were selected for further analysis (0.02% FDR). This gene list was next used to 
cluster 248 UNC breast tumor and normal samples representing all five breast tumor 
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subtypes (Figure 2.3). The list of induced genes from the in vitro SUM102 experiments 
were not homogenously expressed across the tumor samples; therefore, to study these 
multiple expression patterns in the tumors, we defined "clusters" as any gene set that 
contained a minimum of 20 genes and a Pearson node correlation greater than 0.55. 
Using this criteria, we identified three clusters: Cluster #1 was highly expressed in a mix 
of breast tumors that contained all five breast cancer subtypes: luminal A, luminal B, 
basal-like, HER2+/ER- and normal-like samples (Figure 2.3C, far right dendrogram 
branch, 35 genes); Cluster #2 identified a set of tumors that contained 58% of all basal-
like tumors, 48% of all HER2+/ER- tumors and 3 luminal B tumors (Figure 2.3D, center 
dendrogram branch, 27 genes); Cluster #3 was highly enriched for luminal A and B 
tumors, and was also  
 Figure 2.2 
Figure 2.2. Gene expression patterns for SUM102 cells treated with gefitinib or cetuximab. 
Unsupervised hierarchical cluster analysis was performed on 48 h inhibitor treated and 4 h, 8 h, and 24 h 
post 48 hr inhibitor treated samples. A) The complete cluster overview with the colored bars indicating the 
location of the clusters shown in C-G. B) Close up of the experimental sample associated dendrogram. 
C+D) 4 h and 8 h post treatment induced genes including the EGFR ligands Amphiregulin and Epiregulin. 
E) Genes involved with the G1/S phase transition induced beginning in the 4 h post inhibitor and 
continuing through 24 h. F) Genes involved in DNA synthesis induced at 8 h post inhibitor and continuing 
through 24 h. G) Proliferation genes 
 
typically observed in tumor derived profiles including STK6 and Cyclin B1.  
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highly expressed in most of the HER2+/ER- and basal-like tumors that were also high for 
Cluster #2 (Figure 2.3E, left dendrogram branch- luminal A and B tumors, and center 
dendrogram branch  
 
Figure 2.3 
Figure 2.3. In vivo EGFR-associated profiles and additional genes implicated in the EGFR-RAS-
MEK pathway. A) The top 500 induced genes from the SUM102 post treatment experiments were 
hierarchical clustered using the 248 UNC tumors. Colored bars indicate the location of the three clusters in 
D-E. B) Tumor associated dendrogram color coded according to tumor subtype: Luminal A – dark blue, 
Luminal B – light blue, true normals and normal-like – green, HER2+/ER-negative – pink, and basal-like – 
red. C) Cluster #1 that identified a mixed group of tumors. D) Selected genes from the center of Cluster #2 
that are high in most basal-like tumors. E) Selected genes from the center of Cluster #3 that are high in the 
luminal tumors. F) Data for genes with suggested roles in EGFR-pathway. G) Data for the KRAS-amplicon 
signature identified in Herschkowitz et al. 
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Table 2.3 
Table 2.3.  Multivariate Cox Proportional Hazards analysis of EGFR clusters with clinical parameters in 
NKI295 data set 
 
– HER2+/ER- and basal tumors, 139 genes). Thus each gene cluster could represent a 
distinct EGFR-associated signature that is enriched in different subsets of tumors (for full 
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gene lists for each cluster see Appendix IIA). Gene Ontology (GO) analysis using EASE 
was performed on each gene cluster but only Cluster #3 had any significant GO terms, 
which were RNA processing, metabolism, binding, splicing, and modification (EASE 
scores < 0.05). Cyclin E1 was present within Cluster #2 and is a known prognostic 
marker for breast cancer patients (Schraml, Bucher et al. 2003); Cyclin E1 is also 
associated with basal-like breast cancers (Foulkes, Brunet et al. 2004; Sieuwerts, Look et 
al. 2006), which was recapitulated here. Lastly, Cyclin E1 is known to be regulated by 
EGFR-signaling (Navolanic, Steelman et al. 2003), where both AKT and ERK can inhibit 
p27kip1, which is a negative regulator of CDK2/Cyclin E1 complex (Medema, Kops et 
al. 2000; Delmas, Manenti et al. 2001).  
To further examine the biological importance of these three EGFR-associated 
gene sets, we individually applied them to a test set of breast tumors (i.e. the NKI295 
sample set described in (van 't Veer, Dai et al. 2002; Chang, Nuyten et al. 2005)) and 
determine whether they predicted patient outcomes. First, we determined a mean 
expression value of all genes within each cluster for each patient. Next, the patients were 
rank-ordered according to their mean expression values for each cluster and divided into 
halves or thirds. Kaplan-Meier survival analyses for Relapse-Free Survival (RFS) and 
Overall Survival (OS) were performed and all three clusters were statistically significant 
predictors of outcomes where high expression always predicted a poor outcome (Figure 
2.4 – OS; data not shown for RFS). High expression of clusters #2 and #3 were also 
significant predictors of RFS and OS in the UNC training data set (data not shown). 
Using a Cox regression analysis, we tested each cluster with the standard clinical 
parameters and determined that the high expression (top third) of Cluster #2 compared to 
the lowest expression (bottom third) significantly predicted a worse outcome for both 
RFS and OS (Table 2.3) after controlling for age, ER status, size, grade, and node status. 
Since the NKI295 data set was enriched for node-negative tumors less than 5 cm in 
diameter, tumor size and node status were not significant in the multivariate analysis 
(Chang, Nuyten et al. 2005; van't Veer, Paik et al. 2005). Chi-squared analyses were 
performed to identify relations between tumor subtypes and Clusters #1–3. Consistent 
with observations from Figure 2.3, the basal-like, luminal B, and HER2+/ER- tumors 
were associated with the high expression of all three clusters while the luminal A and 
normal-like samples rarely showed high expression (Table 2.4, p =< 0.0001); in 
particular, the majority of basal-like tumors were almost all high for Cluster #2 (89% in 
top 1/3).  
 
Figure 2.4 
Figure 2.4.  Kaplan-Meier survival plots for the 295 NKI tumors/patients using the in vivo defined 
EGFR-associated profiles.  The average expression value for each cluster in each patient was determined 
and the patients then put into rank-order and divided into two equal groups or three equal groups. Overall 
survival analysis was performed for each cluster. X indicates censored data due loss of follow-up data or tol 
lack of information at last checkup. Note that Clusters #2 and #3 were also similarly prognostic for the 
UNC 248 training data set. 
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Analysis of EGFR-pathway components relative to expression patterns in vivo 
Since most of the genes from the in vivo focused EGFR-associated signatures 
were not established members of the HER-signaling pathway, we examined the gene 
expression patterns of many of the known pathway components for their ability to predict 
patient outcomes, and determined if they showed correlations to any of the EGFR-
associated profiles. Gene expression data for three-fourths of the HER family of receptors 
(EGFR, HER2, HER4), some of their ligands (TGFA, EGF, AREG), as well as other 
pathway components including MEK1, MEK2, PIK3CA, PIK3R1, CRYAB, AKT1-3, the 
RAS proteins (H, K and N), ERK1, ERK2, and a KRAS-amplicon signature (identified and 
defined in Herschkowitz et al. (Herschkowitz JI 2007)), were individually tested for the 
ability to predict patient outcomes, for correlations with tumor subtype (Table 2.4), and 
for correlations with the EGFR-associated expression Clusters #1–3 (Table 2.5). Gene 
expression for individual genes was rank-ordered and divided into thirds as was done for 
Clusters #1– 3 previously, and each gene was tested for its ability to predict outcomes in 
the UNC 248 and NKI 295 tumor data sets. No individual gene's expression pattern listed 
above significantly predicted RFS and OS in both the UNC and NKI data sets.  
Associations of genes or clusters with intrinsic subtype  were examined using 
Chi-square analysis and many significant associations were identified (Table 2.4). For 
example, high HER2 expression, as expected, was significantly correlated with the 
HER2+/ER- subtype and high ER expression was associated with both luminal subtypes 
(data not shown). EGFR expression was correlated with the basal-like subtype, while 
high HER4, AREG, and PIK3R1 expression was associated with the luminal A subtype. 
Many other associations with the basal-like subtype were also evident that included the 
high expression of Clusters #1–3, TGFA, AKT3, CRYAB, MEK1, NRAS, KRAS gene and 
the KRAS-amplicon signature (Table 2.4). Other potentially biologically relevant 
associations included the high expression of Clusters #2 and #3, HRAS, MEK1, and AKT1 
with the HER2+/ER- subtype, and high expression of Clusters #1–3 and HRAS with the 
luminal B subtype. Even though Clusters #1–3 were identified using a basal-like tumor 
derived cell line, associations with luminal and HER2+/ER- tumors were identified.  
 
Table 2.4 
Table 2.4. Chi-square analysis for association of gene expression with subtypes.  
Following rank-ordering (most over-expressed to least expressed), all of the samples 
were split into thirds.  The count of each subtype in a third was recorded and ChiSq was 
performed on the resultant table.  Percentages in the table represent samples occupying 
the highest-expressed third. 
 
 
45
  
46
 
We also tested for associations between the high expression of Clusters #1–3 with 
the high expression (i.e. top 1/ 3 highest group) of each of the above-mentioned genes in 
both the UNC and NKI datasets (Table 2.5). In both datasets, the high expression of 
MEK2 and HRAS was associated with Cluster #1, while the high expression of many 
other genes correlated with Clusters 2 and 3; of note was the high expression of the 
KRAS-amplicon, HRAS, NRAS, and MEK1 with both Clusters #2 and #3, and the high 
expression of EGFR with only Cluster #2. The association of different genes with the 
three EGFR-associated signatures is likely reflective of the complexity of signaling in 
this pathway across breast cancers and suggests possible driving molecular mechanisms 
for each EGFR-associated profile.  
Lastly, a previously described mechanism for activation of the EGFR-RAS-MEK 
pathway is the somatic mutation of a RAS gene, BRAF, or EGFR, which can be relatively 
frequent events in non-small cell lung carcinomas. We performed sequencing analyses on 
a subset of the UNC breast tumors analyzed by microarray for EGFR mutations in exons 
19 and 20, and for the common mutations in HRAS, KRAS and BRAF. No somatic 
sequence variants were detected in the 96 tumors that were analyzed, which were over 
sampled for basal-like and HER2+/ER- tumors.   
 
 Table 2.5 
Table 2.5.  Associations between Clusters #1–3 and individual genes using the NKI295 sample set 
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 Figure 2.5 
Figure 2.5.  EGFR pathway diagram displayed for each breast tumor subtype. The average gene 
expression value for each gene within each subtype is displayed for the EGFR-pathway and for the three 
EGFR-activation profiles using the UNC 248 tumor dataset. Eight genes from the middle of each of the 
three EGFR-activation clusters were used to view expression of the clusters in each of the subtypes. A pink 
node border identifies the genes that showed statistically significant associations with subtype. *Note: the 
NKI HER4 data spot was used since HER4 was not present in the UNC data set. A) Luminal A, B) 
Luminal B, C) HER2+/ER- and D) Basal-like. 
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DISCUSSION 
The epidermal growth factor receptor family is of tremendous biological and 
clinical importance for many solid epithelial tumors. In breast cancer patients, the 
response rate to single agent EGFR inhibitors has been low, however, these trials were 
performed on unselected patient populations (Agrawal, Gutteridge et al. 2005; 
Normanno, De Luca et al. 2005) and response rates might be improved within 
biologically selected tumor subsets. The EGFR-pathway has become a potential target in 
the basal-like subtype because at least 50% of basal-like tumors express EGFR as 
assessed by IHC (Nielsen, Hsu et al. 2004). Our in vitro analyses show that all basal-like 
cell lines tested were more sensitive to gefitinib compared to luminal cell lines. Only a 
single cell line (SUM102) was sensitive to cetuximab when EGF was present in the 
media, which is the condition that best mimics the in vivo environment (Singh and Harris 
2005).  
Given the importance of combination therapies, we evaluated the combination of 
cetuximab and various chemotherapeutics in SUM102 cells and observed that the 
combination of cetuximab and carboplatin was highly synergistic at low doses of each 
drug. Even though the short-term co-treatment of cetuximab and carboplatin was 
antagonistic, synergism was observed in the long-term co-treatment. Carboplatin, as well 
as other platinum derivatives, may also be good chemotherapeutic agents for basal-like 
breast cancers due to the implicated function of the BRCA1-pathway in this subtype 
because BRCA1 mutation carriers are likely to develop tumors of the basal-like 
phenotype (Foulkes, Stefansson et al. 2003; Sorlie, Tibshirani et al. 2003; Arnes, Brunet 
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et al. 2005). In our basal-like tumor-derived cell lines, it has been reported that the 
SUM149 line has a BRCA1 mutation and SUM102 line has barely detectable transcript 
levels of BRCA1 (Elstrodt, Hollestelle et al. 2006). From a mechanistic standpoint, 
BRCA1 is required for repair of cisplatin induced DNA damage by recruiting RAD51 to 
the site of damage (Bhattacharyya, Ear et al. 2000; Zhou, Huang et al. 2005) and BRCA1-
deficient cells exhibit increased sensitivity to cisplatin compared to wild type cells 
(Husain, He et al. 1998; Quinn, Kennedy et al. 2003; Tassone, Tagliaferri et al. 2003; 
Kennedy, Quinn et al. 2004). The combination of an EGFR inhibitor and a platinum drug 
has also been found to be synergistic in several other cell types (Ciardiello, Caputo et al. 
2000; Hambek, Baghi et al. 2005; Morelli, Cascone et al. 2005). In our experiments, we 
showed that not only are the basal-like tumor derived cell lines the most sensitive to 
carboplatin and the EGFR inhibitors when applied individually, but also that the 
combination was synergistic. These results provide supportive preclinical evidence for an 
ongoing clinical trial for "triple-negative/basal-like" (i.e. ER-negative, PR-negative, and 
HER2-nonamplified) metastatic breast cancer patients who are receiving either 
cetuximab alone versus cetuximab plus carboplatin (NCT).  
Given the biological importance of the EGFR pathway in epithelial tumors, we 
identified an EGFR-associated profile in vitro and examined its interplay with other 
biological features in vivo. In primary breast tumors, the SUM102- defined set of EGFR-
associated genes was broken into three distinct expression patterns (Figure 2.3), of which 
the high expression of two predicted poor patient outcomes in both the training and test 
data sets (i.e. Clusters #2 and #3). The prognostic ability of these clusters was further 
analyzed in the test set and Cluster #2 could predict poor outcomes even after controlling 
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for the standard clinical parameters in a Cox multivariate analysis. Of the three 
signatures, Cluster #2 was the only cluster significantly associated with high EGFR gene 
expression.  
Since most of the EGFR-associated in vivo profile genes did not have obvious 
functions in the HER family pathway (aside from Cyclin E1 in Cluster #2), we searched 
for correlations with the expression levels of well known genes in the pathway. Many 
relationships were identified that could have important mechanistic implications (Tables 
2.4 and 2.5). To assist in the interpretation of these complex patterns, we used the 
program Cytoscape (Shannon, Markiel et al. 2003) to display the gene expression data in 
a pathway styled format and highlighted the statistically significant associations observed 
within each subtype (Figure 2.5). Each subtype had a distinct EGFR-pathway cartoon 
relative to both the EGFR-associated profiles, as well as the expression of key genes from 
the EGFR-RAS-MEK pathway. The luminal A subtype showed low expression of most 
of the genes we examined in the HER family pathway, and on average, was low for all 
three EGFR-associated profiles. One of the few genes whose high expression was 
significantly correlated with this subtype was the HER4 receptor (Figure 2.5A); high 
expression of HER4 and average expression of two of its ligands (HB-EGF and NRG1) 
was observed in this tumor subtype that typically shows low grade, slow growth, and an 
ER-rich expression signature.  
The luminal B tumors showed moderate to high expression of the EGFR-
associated profiles, high HRAS expression, and potentially high MEK2 expression (Figure 
2.5B). The EGFR-HER2 pathway has often been implicated as a potential mechanism for 
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tamoxifen resistance in ER+ patients (Arpino, Green et al. 2004; Gutierrez, Detre et al. 
2005; Normanno, De Luca et al. 2005; Britton, Hutcheson et al. 2006; Dowsett, 
Houghton et al. 2006; Ellis, Tao et al. 2006). We determined that the high expression of 
the EGFR-associated profiles was able to predict outcome differences in ER+ and 
tamoxifen-treated patients in both the UNC and NKI data sets (data not shown); however, 
it should be noted that the expression of these clusters in ER+ patients closely parallels 
the distinction of luminal A versus luminal B. These results suggest that part of the 
luminal A versus luminal B distinction is due to the activation of the EGFR/HER2 
pathway in luminal B tumors. In support of this hypothesis, ninety-six percent of the 
luminal B tumors showed high expression of at least one of the three EGFR-associated 
clusters,  whereas only 24% of luminal A tumors had high expression of at least one. Our 
results are also consistent with the hypothesis of the "non-genomic" effects of ER to 
activate the HER pathway, where membrane bound ER complexes with EGFR and/or 
HER2 to cause activation of the RASMEK and p38 pathways (Arpino, Green et al. 2004; 
Shou, Massarweh et al. 2004; Gutierrez, Detre et al. 2005), and suggests that these ER 
"non-genomic" effects are occurring in luminal B tumors. Response to EGFR inhibitors 
in ER-positive tumors have been mixed with some indicating a benefit (Polychronis, 
Sinnett et al. 2005; Ciardiello, Troiani et al. 2006), while others found no benefit 
(Dowsett, Houghton et al. 2006). A hypothesis that could be tested is that the high 
expression of one or more of the EGFR-associated gene sets in ER+ tumors might 
correlate with response/benefit to EGFR inhibitors.  
The HER2+/ER- tumors, as expected, showed statistically high expression of 
HER2 and were also associated with high HRAS and MEK1/MEK2 (Figure 2.5C). High 
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AKT1 levels were also associated with this tumor subtype, which has been previously 
identified (Zhou, Tan et al. 2004; Tokunaga, Kimura et al. 2006).  
The basal-like subtype showed the high expression of each of the three EGFR-
associated profiles; ninety-one percent of the basal-like tumors had high expression of at 
least one of the signatures with 58% of the tumors having high expression of all three. 
High expression of many of the genes in the EGFR-RAS-MEK pathway were also 
significantly correlated with the basal-like subtype including EGFR, TGFα, MEK1, 
MEK2, AKT3, CRYAB, NRAS and the KRAS-amplicon signature (Figure 2.5D). For many 
of the genes or clusters examined here, as many as 70% of the basal tumors were in the 
highest 1/3 expression group when compared to all other tumors. These data, when 
coupled to the EGFR inhibitor studies on breast cells lines, strongly suggest that the 
EGFR-RAS-MEK pathway plays an important role in the basal-like subtype's biology, 
and may be a requisite activating event for tumor formation.  
The pathway analysis of the basal-like subtype has also potentially provided 
important mechanistic clues about how the EGFR-RAS-MEK pathway is activated in 
basal-like tumors. One example concerns CRYAB, which has previously been shown to 
be highly expressed in many basal-like tumors and to portend a poor outcome. Moyano et 
al. showed that the ectopic expression of CRYAB in breast epithelial cells caused them to 
become transformed and EGF-independent through activation of MEK (Moyano, Chen et 
al.). This transformed phenotype was reverted by the addition of the MEK inhibitors 
PD98059 and U0126, while the PIK3 inhibitor LY294002 had little effect. CRYAB could 
also potentially confer resistance to EGFR inhibitors as well as chemotherapy by its anti-
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apoptotic mechanism, which is via the inhibition of caspase-3 activation (Kamradt, Chen 
et al. 2001; Lu, Werner et al. 2005). Other potential activation events include the high 
expression of HRAS and KRAS; in particular, the KRAS-amplicon signature (which has 
also been identified in a murine model of basal-like tumors(Liu, Lintig et al. 1998; 
Herschkowitz JI 2007)), was highly expressed in 70% of the basal-like tumors and was 
shown to correlate with high expression of Cluster #2. Given that most basal-like tumors 
showed either high expression of CRYAB or the KRAS-amplicon signature (greater than 
85%), drug targeting of the EGFR-RAS-MEK pathway downstream of EGFR (i.e. MEK 
inhibitors) might offer a more effective therapy than targeting of EGFR directly.  
While these experiments only address gene expression patterns and not the 
protein levels or phosphorylation status of EGFR or RAS or MEK, we believe it is likely 
that these signatures are bona fide EGFR-pathway activation signatures. The supportive 
data for this hypothesis includes the in vitro observations that these are genes induced 
when an EGFR-dependent cell line is freed from growth inhibition via EGFR inhibitors 
and the in vivo associations between the high expression of these signatures and genes 
including HRAS, KRAS and EGFR itself. Regardless of the classical markers of activation 
of the EGFR-RAS-MEK pathway, the strong associations between these expression 
profiles and patient outcomes in two different data sets suggest that they are important 
profiles. Currently, we have chosen only to validate our profiles using additional 
microarray data sets, as opposed to using western blots or quantitative PCR of the 
training set, since each of these signatures represents a large number of genes/proteins. 
Many of these genes have no current link to the EGFR-signaling pathway and we cannot 
be sure of which genes are driving the prognostic significance of the clusters. If these 
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signatures show additional promise for clinical application, detailed follow up will dissect 
which genes are important for prognosis, and then they will be confirmed using other 
platforms. Perhaps another utility of these profiles might be the ability to predict response 
to EGFR inhibitors, however, we could not test this hypothesis, as there are currently no 
large epithelial tumor EGFR inhibitor treated microarray data sets available. However, 
we believe that these signatures could represent a dynamic descriptor of pathway activity 
compared to EGFR protein status alone, which does not predict responsiveness to EGFR 
inhibitors (Fountzilas, Pectasides et al. 2005; Gasparini, Sarmiento et al. 2005).  
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CHAPTER III 
 
FINDING LARGE AVERAGE SUBMATRICES IN HIGH DIMENSIONAL DATA 
 
PREFACE 
 This chapter represents a published co-first-author paper representing a 
collaboration between the Perou and Nobel labs. This work by myself was performed 
alongside Andrey Shabalin, who wrote the algorithm for LAS.  I provided the biological 
relevance to the statistical method and assisted this algorithm with tuning the scoring 
function such that it would produce clusters most like ones that previous studies 
identified first.  I wrote the biological portions of the paper as well as the interpretations 
of the program’s output. The core of the algorithm, the applied statistical framework, as 
well as its interface was written by Dr. Shabalin. 
  
Andrey A. Shabalin, Victor J. Weigman, Charles M. Perou and Andrew  
B. Nobel.  “Finding Large Average Submatricies in High Dimensional 
Data”. Annals of Applied Statistics. 2009. 3 (3). 985-1012. 
 
 
 
 
 
  
64
ABSTRACT 
The search for sample-variable associations is an important problem in the 
exploratory analysis of high dimensional data. Biclustering methods search for sample-
variable associations in the form of distinguished submatrices of the data matrix. (The 
rows and columns of a submatrix need not be contiguous.) In this paper we propose and 
evaluate a statistically motivated biclustering procedure (LAS) that finds large average 
submatrices within a given real-valued data matrix. The procedure operates in an 
iterative-residual fashion, and is driven by a Bonferroni-based significance score that 
effectively trades off between submatrix size and average value. We examine the 
performance and potential utility of LAS, and compare it with a number of existing 
methods, through an extensive three-part validation study using two gene expression 
datasets. The validation study examines quantitative properties of biclusters, biological 
and clinical assessments using auxiliary information, and classification of disease 
subtypes using bicluster membership. In addition, we carry out a simulation study to 
assess the effectiveness and noise sensitivity of the LAS search procedure. These results 
suggest that LAS is an effective exploratory tool for the discovery of biologically 
relevant structures in high dimensional data.   
 
INTRODUCTION 
Unsupervised exploratory analysis plays an important role in the study of large, 
high-dimensional datasets that arise in a variety of applications, including gene 
expression microarrays. Broadly speaking, the goal of such analysis is to find patterns or 
regularities in the data, without ab initio reference to external information about the 
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available samples and variables. One important source of regularity in experimental data 
are associations between sets of samples and sets of variables. These associations 
correspond to distinguished submatrices of the data matrix, and are generally referred to 
as biclusters, or subspace clusters. In gene expression and related analyses, biclusters, in 
conjunction with auxiliary clinical and biological information, can provide a first step in 
the process of identifying disease subtypes and gene regulatory networks. In this paper 
we propose and evaluate a statistically motivated biclustering procedure that finds large 
average submatrices within a given real-valued data matrix.  
The procedure, which is called LAS (for Large Average Submatrix), operates in 
an iterative fashion, and is based on a simple significance score that trades off between 
the size of a submatrix and its average value. A connection is established between 
maximization of the significance score and the minimum description length principle. We 
examine the performance and utility of LAS, and compare it with a number of existing 
methods, through an extensive validation study using two independent gene expression 
datasets. The validation study has three parts. The first concerns quantitative properties of 
the biclustering methods such as bicluster size, overlap and coordinate-wise statistics. 
The second is focused biological and clinical assessments using auxiliary information 
about the samples and genes under study. In the third part of the study, the biclusters are 
used to perform classification of disease subtypes based in their sample membership. In 
addition, we carry out a simulation study to assess the effectiveness and noise sensitivity 
of the LAS search procedure. 
 
Biclustering 
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Sample-variable associations can be defined in a variety of ways, and can take a 
variety of forms. The simplest, and most common, way of identifying associations in 
gene expression data is to independently cluster the rows and columns of the data matrix 
using a multivariate clustering procedure  (Weinstein, Myers et al. 1997; Eisen, Spellman 
et al. 1998; Tamayo, Slonim et al. 1999; Hastie, Tibshirani et al. 2000). When the rows 
and columns of the data matrix are reordered so that each cluster forms a contiguous 
group, the result is a partition of the data matrix into non-overlapping rectangular cells. 
The search for sample variable associations then consists of identifying cells whose 
entries are, on average, bright red (large and positive) or bright green (large and negative)  
(Weigelt, Hu et al. 2005). In some cases, one can improve the results of independent 
row–column clustering by simultaneously clustering samples and variables, a procedure 
known as co-clustering  (Hartigan 1972; Getz, Levine et al. 2000; Dhillon 2001; Kluger, 
Basri et al. 2003). Independent row–column clustering (IRCC) has become a standard 
tool for the visualization and exploratory analysis of microarray data, but it is an indirect 
approach to the problem of finding sample-variable associations. By contrast, biclustering 
methods search directly for sample-variable associations, or more precisely, for 
submatrices U of the data matrix X whose entries meet a predefined criterion. 
Submatrices meeting the criterion are typically referred to as biclusters. It is important to 
note that the rows and columns of a bicluster (and more generally a submatrix) need not 
be contiguous. A number of criteria for defining biclusters U have been considered in the 
literature, for example: the rows of U are approximately equal to each other  (Aggarwal, 
Wolf et al. 1999); the columns of U are approximately equal  (Friedman and Meulman 
2004); the elements of U are well-fit by a 2-way ANOVA model  (Cheng and Church 
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2000; Lazzeroni and Owen 2002; Wang, Wang et al. 2002); the rows of U have equal  
(Ben-Dor, Chor et al. 2003) or approximately equal  (Liu, Yang et al. 2004) rank 
statistics; and all elements of U are above a given threshold  (Prelic, Bleuler et al. 2006). 
The focus of this paper is the simple criterion that the average of the entries of the 
submatrix U is large and positive, or large and negative. Submatrices of this sort will 
appear red or green in the standard heat map representation of the data matrix, and are 
similar to those targeted by independent row–column clustering. 
Features of biclustering 
While its direct focus on finding sample/variable associations makes biclustering 
an attractive alternative to row– column clustering, biclustering has a number of other 
features, both positive and negative, that we briefly discuss below. Row-column 
clustering assigns each sample and each variable to a unique cluster. By contrast, the 
submatrices produced by biclustering methods may overlap, and need not cover the entire 
data matrix, features that better reflect the structure of many scientific problems. For 
example, the same gene can play a role in multiple pathways, and a single sample may 
belong to multiple phenotypic or genotypic subtypes. Multiple bicluster membership for 
rows and columns can directly capture this aspect of experimental data. In row–column 
clustering, the group to which a sample is assigned depends on all the available variables, 
and the group to which a variable is assigned depends on the all the available samples. By 
contrast, biclusters are locally defined: the inclusion of samples and variables in a 
bicluster depends only on their expression values inside the associated submatrix. 
Locality allows biclustering methods to target relevant genes and samples while ignoring 
others, giving such methods greater exploratory power and flexibility than row–column 
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clustering. For more on the potential advantages of biclustering (Jiang, Tang et al. 2004; 
Madeira and Oliveira 2004; Parsons, Haque et al. 2004). Figure 3.1 illustrates the 
differences between the blocks arising from independent row–column clustering and 
those arising from biclustering. Note that while one may display an individual bicluster as 
a contiguous block of variables and samples by suitably reordering the rows and columns 
of the data matrix, when considering more than two biclusters, it is not always possible to 
display them simultaneously as contiguous blocks. The flexibility and exploratory power 
of biclustering methods comes at the cost of increased computational complexity. Most 
biclustering problems are NP complete, and even the most efficient exact algorithms 
(those that search for every maximal submatrix satisfying a given criterion) can be 
prohibitively slow, and produce a large number of biclusters, when they are applied to 
large datasets. The LAS algorithm relies on a heuristic (non-exact), randomized search to 
find biclusters, a feature shared by many existing methods.  
 
RESULTS 
The LAS algorithm 
In this paper we present and assess a significance-based approach to biclustering 
of real-valued data. Using a simple Gaussian null model for the observed data, we assign 
a significance score to each submatrix U of the data matrix using a Bonferroni-corrected 
p-value that is based on the size and average value of the entries of U. The Bonferroni 
correction accounts for multiple comparisons that arise when searching among many 
submatrices for a submatrix having a large average value. In addition, the correction acts 
as a penalty that controls the size of discovered submatrices. (Connections between LAS 
and the Minimum Description Length principle are discussed below.)  
 
Basic model and score function 
Let X = {xi,j: i ∈ [m], j ∈ [n]} be the observed data matrix. (Here and in what 
follows, [k] denotes the set of integers from 1 to k.) A submatrix of X is an indexed set of 
entries U = {xi,j: i ? A, j ? B} associated with a specified set of rows A ? [m] and 
columns B ? [n]. In general, the rows in A and the columns in B need not be contiguous. 
The LAS algorithm is motivated by an additive submatrix model under which the data 
matrix X is expressed as the sum of K constant, and potentially overlapping, submatrices 
plus noise. More precisely, the model states that 
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where Ak ⊆ [m] and Bk ⊆ [n] are the row and column sets of the kth submatrix, τ k ∈ℜ is 
the level of the kth submatrix, and {εij} are independent N (0, 1) random variables. Here 
(·) is an indicator function equal to one when the condition in parentheses holds. When K 
= 0, the model (1) reduces to the simple null model 
 
 under which X is an m×n Gaussian random matrix. The null model (2) leads naturally to 
a significance based score function for submatrices. In particular, the score assigned to a 
k × l submatrix U of X with average Avg (U) = τ  > 0 is defined by 
 
 where Φ is the probability density function of the normal distribution.  The term in 
square brackets is an upper bound on the probability of the event A that there exists a k × 
l submatrix with average greater than or equal toτ in an m × n Gaussian random matrix. 
More precisely, by the union bound, ∑ ≥≤ ))()( τVAvgAP (P , where the sum ranges 
over all k×l submatrices V of X. Under the Gaussian null, each probability in the sum is 
equal to )( klτ−Φ , so that )()( klNAP τ−Φ≥ , where  is the number of k 
× l submatrices of an m× n matrix. From a testing point of view, the term in brackets can 
be thought of as a Bonferroni corrected p-value associated with the null model (2) and the 
test function Avg (U). The score function S (·) measures departures from the null (2) in a 
manner that accounts for the dimensions and average value of a submatrix. It provides a 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
⎟⎟⎠
⎞
⎜⎜⎝
⎛=
l
n
k
m
N
 
 
70
simple, one-dimensional yardstick with which one can compare and rank observed 
submatrices of different sizes and intensities. Among submatrices of the same 
dimensions, it favors those with higher average.   
 
Figure 3.1   
Figure 3.1.  Illustration of bicluster overlap (left) and row–column clustering (right).   
 
Description of algorithm 
The LAS score function is based on the normal CDF, and is sensitive to 
departures from normality that arise from heavy tails in the empirical distribution of the 
expression values. Outliers can give rise to submatrices that, while highly significant, 
have very few samples or variables. As a first step in the algorithm we consider the 
standard Q–Q plot of the empirical distribution of the entries of the column-standardized 
data matrix against the standard normal CDF. Both the breast cancer and lung cancer 
datasets considered exhibited heavy tails. To address this, we applied the transformation I 
(x) = sign (x) log (1+|x|) to each entry  of the data matrix. After transformation, the Q–Q 
plot indicated excellent agreement with the normal distribution. Other alternatives to the 
squashing function f (·) can also be considered.  
The LAS algorithm initially searches for a submatrix of X maximizing the 
significance score S (·). Once a candidate submatrix  has been identified, a residual *U
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matrix X ′
x
 is computed by subtracting the average of  from each of its elements in X. 
Formally, if xi,j is in , and 
*U
ix ,)(
*
,, UAvgx jiji −=′ *U jjix , =′ otherwise. The search 
procedure is then repeated on the residual matrix X ′ . The core of the algorithm is a 
randomly initialized, iterative search procedure for finding a maximally significant 
submatrix of a given matrix. The pseudo code for the algorithm is as follows:  
Input: Data matrix X.  
Search: Find a submatrix  of X that approximately maximizes the score 
function S (·).  
*U
Residual: Subtract the average of  from each of its elements in X.  *U
Repeat: Return to Search.  
Stop: When S ( ) falls below a threshold, or a user-defined number of 
submatrices are produced. 
*U
⎡ ⎤{ }2/,...,1 m
 
The output of the algorithm is a collection of submatrices having significant 
positive averages. Repeating the algorithm with X replaced by −X yields submatrices 
with significant negative averages. It is not feasible in the search procedure to check the 
score of each of the 2n+m possible submatrices of X. Instead, the procedure iteratively 
updates the row and column sets of a candidate submatrix in a greedy fashion until a local 
maximum of the score function is achieved. For fixed k, l, the basic search procedure 
operates as follows:  
Initialize: Select l columns of B at random.  
Loop: Iterate until convergence of A, B: 
Let A := k rows with the largest sum over the columns in B.  
Let B := l columns with the largest sum over the rows in A.  
Output : Submatrix associated with final A, B.  
 
As currently implemented, the initial values of k and l are selected at random 
from the sets and ⎡ ⎤2{ respectively, and are held fixed until the 
algorithm finds a local maximum of the score function. On subsequent iterations, the 
}/,...,1 n
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algorithm adaptively selects the number of rows and columns in order to maximize the 
significance score. Each run of the basic search procedure yields a submatrix that is a 
local maximum of the score function, that is, a submatrix that cannot be improved by 
changing only its column set or its row set. The basic search procedure is repeated 1000 
times, and the most significant submatrix found is returned in the main loop of the 
algorithm. In experiments on real data, we found that 1000 iterations of the main loop of 
the search procedure was sufficient to ensure stable performance of the algorithm.  
Many biclustering methods require the user to specify a number of operational 
parameters, and in many cases, getting optimal performance from the method can require 
careful choice and tuning of the parameters. In addition, for exact algorithms, minor 
alteration of the parameters can result in substantial changes in the size and 
interpretability of the output. The only operational parameters of the LAS algorithm are 
the number of times the basic search procedure is run in each main loop of the algorithm, 
and the stopping criterion. This minimal number of parameters is an important feature of 
LAS, one that makes application of the method to scientific problems relatively 
straightforward.   
 
Penalization and MDL 
The score function employed by LAS can be written as a sum of two terms. The 
first, )(log τkl−Φ− , is positive and can be viewed as a “reward” for finding a k × l 
submatrix with average τ  . The second, , is negative and is a multiple 
comparisons penalty based on the number of k ×l submatrices in X. The penalty depends 
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separately on k and l, and its combinatorial form suggests a connection with the 
Minimum Description Length Principle (MDL)  (Barron, Rissanen et al. 2002; Grunwald 
2004; Rissanen 2006). The MDL principle is a formalization of Occam’s Razor, in which 
the best model for a given set of data is the one that leads to the shortest overall 
description of the data.  
In the Appendix we describe a code for matrices based on a family of additive 
models, and show that the description length of a matrix with an elevated submatrix is 
approximately equal to a linear function of its LAS score. The penalty term in the LAS 
score function corresponds to the length of the code required to describe the location of a 
k ×l submatrix, while the “reward” is related to the reduction in code length achieved by 
describing the residual matrix instead of the original matrix. The connection with MDL 
provides support for the significance based approach to biclustering adopted here.  
 
Description of competing methods.  
In this section we describe the methods to which we will compare the LAS 
algorithm in the validation sections below. We considered biclustering methods that 
search directly for sample variable associations, as well as biclusters derived from 
independent row–column clustering.  
 
Biclustering methods 
Initially, we compared LAS with six existing biclustering methods: Plaid, CC, 
SAMBA, ISA, OPSM, and BiMax. These methods employ a variety of objective 
functions and search algorithms. We limited our comparisons to methods that (i) have 
  
75
publicly available implementations with straightforward user interfaces, (ii) can 
efficiently handle large datasets arising from gene expression and metabolomic data, and 
(iii) are well suited to use by biologists, based on simplistic user interfaces. The methods 
are described in more detail below.  
The Plaid algorithm of Lazzeroni and Owen  (Lazzeroni and Owen 2002)employs 
an iterative procedure to approximate the data matrix X by a sum of submatrices whose 
entries follow a two-way ANOVA model. At each stage, Plaid searches for a submatrix 
maximizing explained variation, as measured by reduction in the overall sum of squares. 
We set the parameters of Plaid so that at each stage it fits a constant submatrix (with no 
row or column effects). With these settings, the Plaid method is most closely related to 
LAS, and also derives from a block-additive model like (1). We have also run Plaid with 
settings under which it fits biclusters by a general ANOVA model. The two versions of 
Plaid exhibit similar validation results; we present only those for which Plaid fits 
biclusters by a constant. Various modifications of the Plaid model and algorithm have 
been proposed in the literature: Turner, Bailey and Krzanowski  (Turner, Bailey et al. 
2005)have developed an improved algorithm and Segal, Battle and Koller  (Segal, Battle 
et al. 2002), Gu and Liu  (Gu and Liu 2008), and Caldas and Kaski  (Caldas and Kaski 
2008) have considered the Plaid problem in the Bayesian framework. We have chosen to 
focus on the original Plaid algorithm, as it is both the first and most representative 
method of its type.  
The Cheng and Church (CC) biclustering algorithm  (Cheng 2000) searches for 
submatrices such that the sum of squared residuals from a two-way ANOVA fit falls 
below a given threshold. These biclusters are locally maximal in the sense that addition 
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of any more rows or columns will increase the mean squared error beyond the threshold. 
Whereas Plaid searches for a submatrix maximizing explained variation, CC searches for 
large submatrices with small unexplained variation. The LAS, Plaid, and CC algorithms 
discover biclusters sequentially. Once a candidate target is identified, LAS and Plaid 
form the associated residual matrix before proceeding to the next stage. By contrast, CC 
replaces the values of the target submatrix by Gaussian noise.  
The SAMBA algorithm of adopts a graph theoretic approach, in which the data 
matrix is organized into a bipartite graph, with one set of nodes corresponding to genes 
and the other corresponding to samples (Tanay, Sharan et al. 2002). Weights are then 
assigned to edges that connect genes and samples based on the data matrix, and the 
subgraphs with the largest overall weights are returned.  
Ihmels developed a biclustering algorithm (ISA) that searches for maximal 
submatrices whose row and column averages exceed preset thresholds  (Ihmels, 
Friedlander et al. 2002). Both LAS and ISA rely on iterative search procedures that are 
variants of EM and Gibbs type algorithms. In both methods, the search procedure 
alternately updates the columnset (given the current rowset) and then the rowset (given 
the current columnset) until converging to a local optimum.  
The OPSM algorithm searches for maximal submatrices whose rows have the 
same order statistics (Ben-Dor, Chor et al. 2003). Like LAS, the OPSM algorithm makes 
use of a multiple comparison corrected p-value in assessing and comparing biclusters of 
different sizes.  
Each of the algorithms above employs heuristic strategies to search for 
distinguished submatrices. By contrast, the Bimax algorithm uses a divide-and-conquer 
approach to find all inclusion-maximal biclusters whose values are above a user-defined 
threshold  (Prelic, Bleuler et al. 2006). Bimax is the only exact algorithm among those 
considered here.  
We ran all methods except Plaid and CC with their default parameter settings. 
LAS, CC, and Plaid allow the user to choose the number of biclusters produced; we 
selected 60 biclusters for each method. The settings of Plaid were chosen so that the 
submatrix fit at each stage is a constant, without row and column effects. Once the CC 
method identifies a bicluster, it removes it from the data matrix by replacing its elements 
by noise. When the CC method was run with the default parameter δ  = 0.5, it initially 
produced a single bicluster that contained most of the available genes and samples, 
leaving very little information from which additional biclusters could be identified. To 
solve this problem, we reduced the δ  parameter in CC from 0.5 to 0.1. A description of 
the computer used to run the biclustering algorithms and the set of parameters used for 
each method is provided in the Appendix.  
 
Independent row–column clustering (IRCC) 
In addition to the methods described above, we also produced biclusters from k-
means and hierarchical clustering. We applied k-means clustering independently to the 
rows and columns of the data matrix, with values of k ranging from 3 to 15. In each case, 
we produced 30 clusterings and selected the one with the lowest sum of within-cluster 
sum of squares. The set of 85×117 = 9945 submatrices (not all column clusters were 
unique) obtained from the Cartesian product of the row and column clusters is denoted by 
KM.  
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We applied hierarchical clustering independently to the rows and columns of the 
data matrix using a Pearson correlation based distance and average linkage. All clusters 
associated with subtrees of the dendrogram were considered, but row clusters with less 
that 10 rows, and column clusters with less than 8 columns, were discarded. The resulting 
set of 34×2806 = 95,404 submatrices obtained from the Cartesian product of the row and 
column clusters is denoted by HC. 
 
Comparison and validation 
Existing biclustering methods differ widely in their underlying criteria, as well as 
the algorithms they employ to identify biclusters that satisfy these criteria. As such, 
simulations based on the additive submatrix model (1) cannot fairly be used to assess the 
performance of competing methods that are based on different models and submatrix 
criteria. For this reason our assessment of LAS relies more heavily on biological 
validation rather than simulations: the former provides a direct comparison of the 
methods in terms of their practical utility.  
We applied LAS and the biclustering methods described in the previous section to 
two existing gene expression datasets: a breast cancer study from Hu et  (Hu, Fan et al. 
2006), and a lung cancer study from Bhattacharjee  (Bhattacharjee, Richards et al. 2001). 
The datasets can be downloaded from the University of North Carolina Microarray 
Database (UMD, http://genome.unc.edu) and http://www.broad.mit.edu/mpr/lung/ 
respectively. In this section we describe and implement a number of validation measures 
for assessing and comparing the performance of the biclustering methods under study. 
The validation results for the breast cancer study are detailed below; the results for the 
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lung cancer data are contained in the Supplementary Materials 
(http://lib.stat.cmu.edu/aoas/239/supplement.pdf). The validation measures considered 
here are applicable to any biclustering method and most gene expression type datasets. 
 
Description of the Hu data 
This dataset is from a previously published breast cancer study  (Hu, Fan et al. 
2006) that was based on 146 Agilent 1Av2 microarrays. Initial filtering and 
normalization followed the protocol in Hu et al.: genes with intensity less than 30 in the 
red or green channel were removed; for the remaining genes, red and green channels 
were combined using the log2 ratio. The initial log-transformed dataset was row median 
centered, and missing values were imputed using a k-nearest neighbor algorithm with k = 
10. Among the 146 samples, there were 29 pairs of biological replicates in which RNA 
was prepared from different sections of the same tumor. To avoid giving these samples 
more weight in the analysis, we removed the replicates, keeping only the primary tumor 
profiles. After preprocessing, the dataset contained 117 samples and 13,666 genes. In 
what follows, the dataset will be referred to as Hu.  
 
Quantitative comparisons 
LAS, Plaid, and CC were set to produce 60 biclusters. The number of biclusters 
produced by other methods was determined by their default parameters, with values 
ranging from 15 (OPSM) to 1977 (BiMax). KM and HC produced 9945 and 95,404 
biclusters, respectively. Table 3.1 shows the number of biclusters produced by each 
method.  
All biclustering methods were run on the same computer, having an AMD64 FX2 
Dual Core processor with 4GB of RAM (a complete specification is provided in the 
Appendix). The running time of LAS was 85 minutes; ISA and OPSM finished in about 
30 minutes; CC, Plaid, and SAMBA finished in less then 10 minutes. The Bimax 
algorithm took approximately 5 days. Hierarchical clustering took 2 minutes, while k-
means clustering (with k = 3, . . . , 15 and 30 repeats) took 1 hour 40 minutes. Our 
primary focus in validation was output quality.  
 
Table 3.1 
 
Table 3.1.  Output summary for different biclustering methods. From left to right: total number of 
biclusters produced; effective number of biclusters; the ratio of the effective number to the total number of 
biclusters 
 
Bicluster sizes 
In Figure 3.2 we plot the row and column dimensions of the biclusters produced 
by the different methods. The resulting scatter plot shows marked differences between 
the methods under study, and provides useful insights into their utility and potential 
biological findings. (A similar figure could be used, for example, to assess the effects of 
different parameter settings for a single method of interest.) Both LAS and CC produce a 
relatively wide range of bicluster sizes, with those of LAS ranging from 8 × 8 (genes × 
samples) to 1991 × 55. The other methods tested produced biclusters with a more limited 
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range of sizes. Biclusters produced by ISA, OPSM, and SAMBA have a relatively small 
number of samples, less than 10 samples per bicluster on average in each case. (Some of 
the points denoting OPSM clusters have been obscured in the figure.) The biclusters 
produced by Bimax had at most 8 samples, and at most 18 genes. By contrast, Plaid 
produced large biclusters, having an average of 49 samples and 5130 genes per bicluster.  
 
Figure 3.2 
 
Figure 3.2.  Bicluster sizes for different methods. 
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The differences between LAS and Plaid bear further discussion. We ran Plaid 
with settings (constant fit, no row, and column effects) that made it most similar to LAS. 
With these settings, both methods rely on similar models, and proceed in stages via 
residuals, but differ in their objective functions. Plaid seeks to maximize the explained 
variation ,or equivalently, 2τkl )(log τkl−Φ− .  By contrast, the score function 
maximized by LAS includes a combinatorial penalty term involving k and l that acts to 
control the size of the discovered submatrices. In this, and other, experiments, the penalty 
excludes very large submatrices, and produces a relatively wide range of bicluster sizes. 
(While the combinatorial penalty is small for values of k close to m and l close to n, 
submatrices of this size tend to have a small average value.)  
 
Effective number of biclusters 
Distinct biclusters produced by the same method may exhibit overlap. On the one 
hand, the flexibility of overlapping gene and sample sets has the potential to better 
capture underlying biology. On the other hand, extreme overlap of biclusters can reduce a 
method’s effective output: two moderate sized biclusters that differ only in a few rows or 
columns do not provide much more information than either bicluster alone. Whatever the 
source of overlap, it is helpful to keep it in mind when evaluating other features of a 
method, such as the number of biclusters it produces that are deemed to be statistically 
significant. To this end, we measure the effective number of biclusters in a family U1, . . . 
,UK by: 
 where  is the number of biclusters containing matrix entry x. The 
measure F (·) has the property that if, for any 1 ≤ r ≤ K, the biclusters U1, . . . ,UK can be 
divided into r nonoverlapping groups of identical biclusters, then F (U1, . . . ,UK) = r.  
∑
=
∈=
K
k
kUxIxN
1
}{)(
Table 3.1 shows the effective number of biclusters produced by each method. The 
low overlap of the CC algorithm is due to the fact that it replaces the values in discovered 
submatrices by Gaussian noise, so that a matrix element is unlikely to belong to more 
than one bicluster. Bimax is an exhaustive method with no pre-filtering of its output; it 
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produced a large number of small, highly overlapping biclusters. Biclusters produced by 
LAS had modest levels of overlap, less than those of all other methods, except CC. The 
high overlap of Plaid biclusters is explained in part by their large size. 
 
Score-based comparison of LAS and standard clustering 
Ideally, a direct search for large average submatrices should improve on the 
results of independent row–column clustering. To test this, we computed the significance 
score S (C) for every cluster produced by KM and HC, and compared these to the scores 
obtained with LAS. The highest scores achieved by KM and HC biclusters were 6316 
and 5228, respectively. The first LAS biclusters had scores 12,883 (positive average) and 
10,070 (negative average); the scores of the first 6 LAS biclusters were higher than 
scores of all the biclusters produced by KM or HC. The highest score achieved by a Plaid 
bicluster was 12,542, which also dominated the scores achieved by KM and HC. These 
results show that LAS is capable, in practice, of finding submatrices that cannot be 
identified by standard clustering methods. We also note that LAS produces only 60 
biclusters, while KM and HC produce 9945 and 95,404 biclusters, respectively. 
 
Summary properties of row and column sets 
One potential benefit of biclustering methods over independent row–column 
clustering is that the sample-variable associations they identify are defined locally: they 
can, in principle, identify patterns of association that are not readily apparent from the 
summary statistics across rows and columns that drive k-means and hierarchical 
clustering. Nevertheless, local associations can sometimes be revealed by summary 
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measures of variance and correlation, and it is worthwhile to consider the value of these 
quantities as a way of seeing (a) what drives different biclustering methods, and (b) the 
extent to which the local discoveries of these methods are reflected in more global 
summaries.  
For each method under study, the first four columns of Table 3.2 show the 
average, across the biclusters, of the following summary statistics: (i) the average pair-
wise correlation of the gene membership of clusters, (ii) the average pairwise correlation 
of their constituent samples, (iii) the average standard deviation of their constituent 
genes, and (iv) the average standard deviation of their constituent samples. Average 
values for the entire matrix are shown in the first row of the table. (Recall that the data 
matrix is column standardized, so the column standard deviations are all equal to one.) In 
each case, the statistics associated with the biclustering methods are higher than the 
average of these statistics over the entire matrix. As HC is based entirely on gene and 
sample correlations, we expect its correlation values to be large compared with other 
methods, and this is the case. The moderate values of gene correlation for KM result from 
the fact that we are using a relatively small numbers of gene clusters, which tend to have 
a large number of genes and therefore low average pairwise correlations. Similar remarks 
apply to the low gene (and sample) correlation values associated with Plaid.  
BiMax appears to be driven by all summary measures, with gene correlation 
playing a relatively minor role, while ISA is not affected by gene standard deviation. 
LAS appears to be driven by a mix of gene correlation and standard deviation. The 
average summary statistics of LAS do not appear to be extreme, or to reflect overtly 
global behavior. In each column, the average for LAS is less than and greater than those 
of two other methods. The remaining biclustering methods appear to depend on two, or in 
some cases only one, of the measured summary statistics. We note that the average 
pairwise correlation of the samples in LAS biclusters best matches the average pairwise 
correlation of samples in the cancer subtypes (described below).  
 
Table 3.2 
 
Table 3.2.  Average standard deviation and average pairwise correlation of genes and samples, for 
biclusters, KM and HC clusters, and the whole data matrix. As a reference point, the last row shows the 
summary statistics for samples belonging to the same disease subtype 
 
Tightness of biclusters 
For each method under consideration we calculated the average of the within 
bicluster variances. The results are presented in the rightmost column of Table 3.2. 
BiMax and SAMBA, which operate on thresholded entries, find biclusters with high 
average variance. LAS, Plaid, and ISA search for biclusters with high overall or high 
row/column averages; they find biclusters with variance above one. Biclusters identified 
by the CC algorithm have the smallest average variance, as CC searches for biclusters 
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with low unexplained variation. The IRCC methods find biclusters with average variance 
only slightly lower that one.  
 
Biological comparisons 
The previous section compares LAS with other biclustering and IRCC methods 
on the basis of quantitative measures that are not directly related to biological or clinical 
features of the data. In this section we consider several biologically motivated 
comparisons. In particular, we carry out a number of tests that assess the gene and sample 
sets of each bicluster using auxiliary clinical information and external annotation. The 
next subsection considers sample-based measures of subtype capture. 
 
Subtype capture 
Breast cancer encompasses several distinct diseases, or subtypes, which are 
characterized by unique and substantially different expression signatures. Each disease 
subtype has associated biological mechanisms that are connected with its pathologic 
phenotype and the survival profiles of patients (Golub, Slonim et al. 1999; Sorlie, Perou 
et al. 2001; Weigelt, Hu et al. 2005; Hayes, Monti et al. 2006). Breast cancer subtypes 
were initially identified using hierarchical clustering of gene expression data, and have 
subsequently been validated in several datasets  (Fan, Oh et al. 2006) and across 
platforms  (Sorlie, Tibshirani et al. 2003). They are one focal point for our biological 
validation. Hu assigned each sample in the dataset to one of 5 disease subtypes (Basal-
like, HER2-enriched, Luminal A, Luminal B, and Normallike) using a nearest shrunken 
centroid predictor (Tibshirani, Hastie et al. 2002) and a pre-defined set of 1300 intrinsic 
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genes. The centroids for the predictor were derived from the hierarchical clustering of 
300 samples chosen both for data quality and the representative features of their 
expression profiles. In addition, each sample in the Hu dataset was assigned via a clinical 
assay to one of two estrogen receptor groups, denoted ER+ and ER−, which constitute the 
ER status of the tumor. The ER status of tumors is closely related to their subtypes: in the 
Hu dataset, HER2-enriched and Basallike samples are primarily ER-negative (74% and 
94% respectively), while Normal-like, Luminal A and Luminal B are primarily ER-
positive (83%, 86%, and 91% respectively).  
Here we compare the ability of biclustering methods to capture the disease 
subtype and ER status of the samples. In order to assess how well the set of samples 
associated with a bicluster captures a particular subtype, we measured the overlap 
between the two sample groups using a p-value from a standard hypergeometric test 
(equivalent to a one-sided Fisher’s exact test). For each biclustering method, we 
identified the bicluster that best matched each subtype, and recorded its associated p-
value. As a point of comparison, we include the subtype match of column clusters 
produced by k-means and hierarchical clustering. The results are shown in Figure 3.3.  
The figure indicates that LAS captures ER status and disease subtypes better than 
the other biclustering methods, with the single exception of the Luminal A subtype, 
which was better captured by CC. In addition, LAS is competitive with KM and HC, 
performing better or as well as these methods on the Luminal A, Luminal B, Basal-like, 
and HER2-enriched subtypes.  
 
Figure 3.3 
 
Figure 3.3.  The –log10 p-values of best subtype capture for different biclustering and sample 
clustering methods 
 
Another view of subtype capture is presented in the bar-plot of Figure 3.4. For the 
Basal-like disease subtype, the figure shows the number of true, missed, and false 
discoveries associated with the the best sample cluster (as judged by the hypergeometric 
p-value) that was produced by each method. The Basal-like subtype contains 32 samples. 
The best LAS bicluster captured 27 of the 32 Basal-like samples with no false positives. 
Plaid had fewer missed samples, but a larger number of false positives, due to the large 
size of its sample clusters. As the disease subtypes were identified in part through the use 
of hierarchical clustering, the strong performance of KM and HC is unsurprising. Other 
biclustering methods were not successful in capturing Basal-like or other subtypes, due in 
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part to the small number of samples in their biclusters. Bar plots like Figure 3.4 for other 
subtypes are provided in the Supplementary Materials. 
 
Figure 3.4 
 
Figure 3.4.  Bar-plot of missed, true, and false discoveries for different biclustering methods and the 
Luminal A subtype. Bars represent: light—missed discoveries, dark—true discoveries, gray—false 
discoveries. 
 
Biclusters of potential biological interest 
In order to assess the potential biological and clinical relevance of the biclustering 
methods under consideration, we applied three different tests to the gene and sample sets 
of each bicluster. The first test makes use of clinical information concerning patient 
survival. The second tests for over-representation of functional categories and genomic 
neighborhoods (cytobands) among the gene sets of different biclusters, and the third tests 
for the differential expression of these same gene categories between the sample set of a 
bicluster and its complement. The tests are described in more detail below.  
We chose not to include KM and HC in this analysis for several reasons. The tests 
conducted here are intended to provide a rough biological assessment of the gene and 
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sample sets of biclusters that are produced with the primary goal of capturing gene-
sample associations. In this sense, the tests here are assessing secondary features of these 
methods. By contrast, gene and sample based tests are separately assessing the primary 
features of KM and HC, for which biclusters are a byproduct of their independent gene 
and sample grouping.  
For 105 samples out of 117 in the dataset, we have information regarding overall 
survival (OS) and relapse free survival (RFS). We applied the standard logrank test  
(Bewick, Cheek et al. 2004) to determine if there are significant differences between the 
survival times associated with samples in a bicluster and the survival times associated 
with samples in its complement. Biclusters whose associated patients have significantly 
lower (or higher) survival rates are of potential clinical interest, as their gene sets may 
point to biological processes that play a deleterious (or beneficial) role in survival. A 
bicluster was called significant if its samples passed the logrank test for overall or relapse 
free survival at the 5% level. The number of biclusters meeting the criterion is presented 
in the Survival column of Table 3.3.  
We next tested the gene set of each bicluster for over-representation of 
biologically derived functional categories and genomic neighborhoods. For the former, 
we considered KEGG categories [ (Kanehisa and Goto 2000), 
http://www.genome.jp/kegg/]. For the latter we considered cytobands, which consist of 
disjoint groups of genes such that the genes in a group have contiguous genomic 
locations. Definitions of KEGG and cytoband categories were taken from R metadata 
packages on Bioconductor (Bioconductor v 1.9, packages hgug4110b and hgu95av2).  
 
 Table 3.3 
Table 3.3. The number of biclusters passing tests for survival, and gene-set enrichment and sample-
set differential expression of KEGG categories and cytobands. A detailed description of the tests is 
given in the text 
 
For each bicluster gene set we computed a Bonferroni corrected hypergeometric 
p-value to assess its overlap with each KEGG category, and computed a similar p-value 
for each cytoband. We considered 153 KEGG categories and 348 cytobands that 
contained at least 10 genes (post filtering) on our sample arrays. A gene set was deemed 
to have significant overlap if any of the p-values computed in this way was less than 
10−10. This threshold was selected to adjust for the anti-conservative behavior of the 
hypergeometric test in the presence of even moderate levels of gene correlation  (Barry, 
Nobel et al. 2005). The column Gene of Table 3.3 shows the number of biclusters having 
signficant overlap with at least one KEGG category or cytoband. The third test concerns 
the differential expression of KEGG and cytoband categories across the sample set of a 
bicluster and its complement. From each bicluster we formed a treatment group 
consisting of the samples in the bicluster and a control group consisting of the 
complementary samples that are not in the bicluster. We tested for KEGG categories 
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showing differential expression across the defined treatment and control groups using the 
SAFE procedure and counted the number of categories passing the test at the 5% level. 
The permutation based approach in SAFE accounts for multiple comparisons and the 
(unknown) correlation among genes. A similar testing procedure was carried out for 
cytobands.  
If no KEGG category were differentially expressed across the treatment and 
control groups corresponding to a particular bicluster, roughly 5% of the categories 
would exhibit significant differential expression by chance. We considered a bicluster 
sample set to yield significant differential expression of KEGG categories if the number 
of significant categories identified by SAFE exceeds the 5th percentile of the Bin (153, 
0.05) distribution. An analogous determination was made for cytobands. The number of 
biclusters whose sample sets yield significant differential expression for KEGG 
categories or cytobands is presented in the Sample column of the Table 3.3.  
The rightmost columns of Table 3.3 show the number of biclusters passing two or 
three tests. From an exploratory point of view, these biclusters are of potential interest, 
and represent a natural starting point for further experimental analysis. Accounting for 
the number (or effective number) of biclusters produced by each method, specifically the 
large output of SAMBA and the small output of OPSM, LAS outperformed the other 
methods under study, particularly in regards to biclusters satisfying two out of the three 
tests. 
 
Classification 
 Biclustering algorithms identify distinct sample-variable associations, and in 
doing so, can capture useful information about the data. To assess how much information 
about disease subtypes and ER status is captured by the set of biclusters produced by 
different methods, we examined the classification of disease subtypes using patterns of 
bicluster membership in place of the original expression measurements. Similar 
applications of biclustering for the purpose of classification were previously investigated  
(Tagkopoulos, Slavov et al. 2005) and unpublished work  (Grothaus 2005; Asgarian and 
Greiner 2006).  
 Once biclusters have been produced from the data matrix, we replaced each 
sample by a binary vector whose jth entry is 1 if the sample belongs to the jth bicluster, 
and 0 otherwise. A simple k-nearest neighbor classification scheme based on weighted 
Hamming distance was applied to the resulting binary matrix: the classification scheme 
used the subtype assignments of training samples to classify unlabeled test samples. The 
number of rows in the derived binary matrix is equal to the number of biclusters; in every 
case this is far fewer than the number of genes in the original data. To be more precise, 
let X = [x1, . . . ,xn] be an m×n data matrix, and let C1, . . . ,CK be the (index sets of) the 
biclusters produced from X by a given biclustering method. We map each sample 
(column) xi into a binary vector that encodes its bicluster 
membership: 
t
iKii xxx ))(),...,(()( 1 πππ =
 
 The original data matrix X is then replaced by the K ×n “pattern” matrix 
)}(),...,({ 1 nxx ππ=Π . In the Hu data, for example, the 13,666 real variables in X are 
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replaced by K < 300 binary variables in Π . Subtype and ER designations for the initial 
data matrix X carry over to the columns of Π . For each of the breast cancer subtypes in 
the Hu data, we used 10-fold cross validation to assess the performance of a 5-nearest 
neighbor classification scheme applied to the columns of the binary pattern matrix Π . 
The nearest neighbor scheme used a weighted Hamming distance measure, in which the 
weight of each row is equal to the square of the t-statistic for the correlation r between the 
row and the response, 
)1(
)2(2 2
2
r
rnt −
−= . In each case, the weights were calculated using 
only the set of training samples. For each subtype, the average number of cross-validated 
errors was divided by the total number of samples, in order to obtain an overall error rate. 
The results are displayed in Figure 3.5. For comparison, we include 10-fold cross 
validation error rates of a support vector machine (SVM) classifier applied to the original 
expression matrix X. As the figure shows, the error rates of LAS and Plaid are similar to 
those of SVM across the phenotypes under consideration. Using the pattern information 
from 60 biclusters, LAS and Plaid were able to distinguish individual subtypes with the 
same degree of accuracy as SVM applied to the original data with 13,666 variables.  
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 Figure 3.5 
Figure 3.5.  Classification error rates for SVM on the original data and the 5-nearest neighbor 
with weighted Euclidean distance applied to the “pattern” matrix. 
 
Lung data 
 Validation results for the lung cancer data are contained in the Supplementary 
Materials. They are similar to the results for the breast cancer data considered above. The 
principal difference was the improved performance of ISA in tests of subtype capture. 
While ISA biclusters continued to have small sample sets, the disease subtypes for the 
lung data contained fewer samples than those in the breast data. 
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Simulations 
 In addition to real data, we also investigated the behavior of the LAS algorithm on 
a variety of artificially created datasets. Our primary goals were to assess (i) the ability of 
the algorithm to discover significant submatrices under the additive model (1), (ii) the 
stability of the algorithm with respect to the initial random number seed, and (iii) the 
sensitivity of the algorithm to noise. The results of these simulations are described below. 
All relevant figures and tables (except Table 3.4) appear in the Supplementary Materials.  
 
Null model with one embedded submatrix 
 The key step of the LAS algorithm is to identify a submatrix of a given matrix 
that maximizes the score function. The approach taken by LAS is heuristic. As there are 
no efficient algorithms for finding optimal matrices, outside of small examples, we 
cannot check directly if the submatrix identified by LAS is optimal. In order to evaluate 
the LAS search procedure, we generated a number of data matrices of the same size as 
the Hu dataset, with i.i.d. N (0, 1) entries. For k = 4, 8, 16, . . . , 4096 and l = 4, 8, 16, 32, 
we added a constant α  = 0.1, 0.2, . . . , 1 to a k × l submatrix of the initial Gaussian 
matrix. The basic LAS search was carried out on each of the 11 × 4 × 10 = 440 resulting 
matrices, and was considered a success if the search returned a bicluster whose score was 
at least as high as that of the embedded submatrix. The LAS search failed in only three 
cases; in each the embedded submatrix had relatively low scores (less than 100, while 
scores of other submatrices ranged up to 61,415.5). The search procedure was successful 
in all cases when the number of iterations used in the procedure was increased from 1000 
to 10,000.  
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Table 3.4 
 
Table 3.4.  Discovery of multiple biclusters.  For a set of biclusters produced by the simulations, the 
match value represents the overlap that would exist without a measure for similar content in 
embedded clusters. 
 
Null model with multiple embedded submatrices 
 We also tested the ability of LAS to discover multiple embedded submatrices. 
Simulations were performed with a varying number of embedded biclusters (up to 50), 
with 10 simulations for each number of biclusters. In each simulation, we first generated 
a 1000 × 1000 Gaussian random matrix. Then we randomly selected size and position of 
each bicluster, independently assigning rows and columns of the matrix to the bicluster 
with probability 0.02, so that the expected size of a bicluster is 20 × 20. Biclusters were 
generated independently, allowing for overlap. The elements of every bicluster were 
raised by 2 and LAS was applied to the resulting matrix. LAS was set to search for the 
correct number of biclusters with the default 1000 iterations per bicluster. For every 
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embedded bicluster U, we assessed its overlap with each detected bicluster ˜U using the 
minimum of specificity |U ∩ ˜U |/|U| and sensitivity |U ∩ ˜U |/|˜U |, equivalently, |U ∩ ˜U 
|/max (|U|, | ˜ U|), and matched U with the closest ˜U . The average overlap across 
embedded biclusters and simulations for each number of true biclusters is presented in 
Table 3.4. The numbers indicate consistent accuracy of LAS in the detection of multiple 
embedded biclusters. 
 
Stability 
 In order to check the stability of LAS with respect to the randomization used in 
the basic search procedure, we ran the algorithm 10 times on the Hu dataset with different 
random seeds. In order to assess the performance of the algorithm, rather than its raw 
output, for each of the 10 runs we calculated the validation measures: effective number of 
biclusters, average size, p-values for subtype capture and the number of biclusters that 
passed different biological tests. The results are presented in the Supplementary 
Materials. There is little variation in the calculated measures across different runs of the 
algorithm. The effective number of biclusters ranged from 48.2 to 49.0, and average size 
ranged from 355 × 26 to 363 × 27. The number of biclusters with significant survival 
ranged from 9 to 13, and the number of biclusters having significant overlap with at least 
one KEGG category or cytoband ranged from 13 to 16. The SAFE analysis is 
computationally intensive, so we did not perform it for these simulations. Although the 
output of LAS is not deterministic, its summary statistics for average size and overlap are 
stable, and it is consistently successful in capturing cancer subtypes. 
 
Noise sensitivity 
 In order to assess the effects of noise on the LAS output, we added zero mean 
Gaussian noise with standard deviation σ  = 0, 0.1, 0.2, . . . , 1 to the normalized Hu 
dataset (after tail transformation and column standardization). The resulting matrix was 
then column standardized, and LAS was applied to produce 60 biclusters. For each level 
of noise we calculated validation measures for the LAS output; these are presented in the 
Supplementary Materials.  As the level of noise increases, the average number of genes in 
the LAS biclusters decreased, as did the number of biclusters having a significant 
association with Cytoband or KEGG categories. However, within the tested range of 
noise levels, the average number of samples did not change noticeably, and the subtype 
capture performance did not markedly decrease. The results indicate both high noise 
resistance of LAS and the strength of subtype signal.   
 
DISCUSSION   
Biclustering methods are a potentially useful means of identifying sample-
variable associations in high-dimensional data, and offer several advantages over 
independent row–column clustering. Here we have presented a statistically motivated 
biclustering algorithm called LAS that searches for large average submatrices. The 
algorithm is driven by a simple significance-based score function that is derived from a 
Bonferroni corrected p-value under a Gaussian random matrix null model. We show that 
maximizing the LAS score function is closely related to minimizing the overall 
description length of the data in an additive submatrix Gaussian model (for full 
description of MDL and ODL, see http://lib.stat.cmu.edu/aoas/239/supplement.pdf).  
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The LAS algorithm operates in a sequential-residual fashion; at each stage the 
search for a submatrix with maximum score is carried out by a randomly initialized 
iterative search procedure that is reminiscent of EM type algorithms. The only 
operational parameters of LAS are the number of biclusters it produces before halting, 
and the number of randomized searches carried out in identifying a bicluster. In our 
experiments on real data, we found that 1000 randomized searches per bicluster were 
sufficient to ensure stable performance of the algorithm.  
We evaluated LAS and a number of competing biclustering methods using a 
variety of quantitative and biological validation measures. On the quantitative side, LAS 
produced biclusters exhibiting a wide range of gene and sample sizes, and low to 
moderate overlap. The former feature implies that LAS is capable of capturing sample-
variable associations across a range of different scales, while the latter indicates that 
distinct LAS biclusters tend to capture distinct associations. Other methods varied 
considerably in their sizes and overlap, with a number of methods producing biclusters 
having a small number of samples and genes.  
Many LAS biclusters had significantly higher scores than biclusters obtained by 
more traditional approaches based on k-means and hierarchical 24 S clustering. This 
suggests that the constraints associated with independent row–column clustering 
(considering rows and columns separately, assigning each row or column to a single 
cluster) substantially limit the ability of these methods to identify significant biclusters, 
and that more flexible methods may yield substantially better results.  
In regards to capturing disease subtypes, LAS was competitive with, and often 
better than, KM and HC. Other methods did not perform particularly well, though we 
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note that ISA did a good job of capturing and classifying the smaller disease subtypes 
present in the lung cancer data. In tests for survival, over-representation of functional 
categories, and differential expression of functional categories, LAS outperformed the 
other biclustering methods. These tests, unlike the quantitative measures of size and 
overlap, were based on clinical and biological information.  
The classification study above shows that simple binary profiles of bicluster 
membership can contain substantive information about sample biology. In particular, 
nearest neighbor classification of disease subtypes using membership profiles derived 
from LAS or Plaid biclusters was competitive with a support vector machine classifier 
applied to the full set of expression data. We note that the biclustering methods applied 
here are unsupervised, and depend only on the expression matrix: none makes use of 
auxiliary information about samples or variables.  
Our simulation study shows that the LAS search procedure is effective at 
capturing embedded submatrices (or more significant ones) having moderate scores. 
Although the search procedure makes use of random starting values, its performance is 
stable across different random seeds. The ability of the algorithm to capture subtypes 
does not substantially deteriorate when a moderate amount of noise is added to the data 
matrix.  
While the validation of biclustering here has focused on gene expression 
measurements, it is important to note that LAS and other biclustering methods are 
applicable to a wide variety of high-dimensional data. In preliminary experiments on high 
density array CGH data produced on the Agilent 244k Human Genome CGH platform, 
LAS was able to capture known regions of duplications and deletion (data not shown). 
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The dataset contained roughly 250 samples and 240,000 markers. We note that among 
the seven biclustering methods compared in the paper only the current implementations 
of LAS and Plaid were able to handle datasets of this size.  
LAS biclusters capture features of the data that are of potential clinical and 
biological relevance. Although some findings, such as disease subtypes, are already 
known, very often the methods used to establish them involve a good deal of subjective 
intervention by biologists or disciplinary scientists. LAS provides a statistically 
principled alternative, in which intervention (such as selecting biclusters of potential 
interest) can take place after the initial discovery process is complete. We note that the 
LAS score function and search procedure can readily be extended to higher dimensional 
arrays, for example, three-dimensional data matrices of the form {xi,j,k : i ∈ [m], j ∈ [n], k ∈ 
[p]}. Related extensions of the Plaid model have been developed  (Turner, Bailey et al. 
2005).  
As noted, our use of the large average criterion is motivated by current biological 
practice in the analysis of gene expression and related data types. The validation 
experiments in the paper establish the efficacy of the large average criterion, and the LAS 
search procedure, for standard gene expression studies, and there is additional evidence to 
suggest that the criterion will be effective in the analysis of CGH data. Nevertheless, we 
note that the large average criterion is one of many that may be used in the exploratory 
analysis of high dimensional data. Other criteria and methods can offer additional 
insights into a given data set of interest, and may provide valuable information in cases, 
and for questions, where the large average criterion is not appropriate.  
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CHAPTER IV 
 
BASAL-LIKE BREAST CANCER DNA COPY NUMBER LOSSES IDENTIFY 
GENES INVOLVED IN GENOMIC INSTABILITY, RESPONSE TO THERAPY AND 
PATIENT SURVIVAL 
 
PREFACE 
 This chapter represents a manuscript focusing on identifying tumor subtype 
specific DNA copy number events. This study required significant integration and 
analyses across gene expression and DNA copy number genomic platforms. I outlined 
the analyses presented and designed new CNA identification software, SWITCHdna, 
which is especially geared for aCGH studies and is capable of making calls on newer, 
highly-resolved arrays.  Following the initial biological and informatics analysis to 3 key 
genes lost on 5q, George Chao assisted me in identifying their in vitro biological impact.  
The inner segment-calling algorithm of SWITCHdna was also co-developed by Andrey 
Shabalin, to which I transcribed into the R language and provided graphical interpretation 
and multiple testing correction. 
V.J. Weigman, H. H. Chao, A. S. Shabalin, X. He, J.S. Parker, S.A. Nordgard,  
A. Nobel, Anne-Lise Børresen-Dale,  and C. M. Perou.  “Basal-like Breast 
tumor enriched DNA copy number losses lead to identification of key 
genes involved in genomic instability, response to therapy, and patient 
survival”.  Manuscript in preparation. 
ABSTRACT 
 Breast cancer is a heterogeneous disease with known tumor subtypes. In order to 
gain insight into the underlying etiologies of these disease subtypes, we first classified 
tumors according to breast cancer intrinsic subtypes, and second, identified subtype 
enriched tumor genomic DNA copy number alterations (CNA) using a novel method 
called SWITCHdna.  All tumor subtypes showed specific CNA, however, Basal-like 
breast cancers were the most distinct and associated with loss to RB1, TP53, PTEN, and 
showed the largest number of alterations.  A common Basal-like CNA was loss of 
chromosome 5q that contained at least three genes important for DNA repair (RAD17, 
RAD50, and RAP80), and which were predominantly lost in pairs or all three. Loss of 
two or three of these genes was associated with significantly increased genomic 
instability as defined by the absolute number of CNA, and poor patient survival. RNAi 
knockdown of RAD17, or RAD17 and RAD50 caused a sensitization to treatment with a 
PARP inhibitor, or carboplatin, in an immortalized HMEC line.  These data suggest a 
mechanism for genomic instability in Basal-like breast cancers and a biological rationale 
for the use of DNA repair inhibitor related therapeutic agents in this aggressive breast 
cancer subtype.  
 
INTRODUCTION 
Previous gene expression profiling studies of human breast tumors have shaped 
our understanding that breast cancer is not one disease, but is in fact many biologically 
separate diseases. A classification of tumors into five distinct groups including the 
Luminal A, Luminal B, HER2-enriched, Basal-like, and Claudin-low subtypes, has added 
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prognostic and predictive value to the existing repertoire of biomarkers for breast cancer 
(Prat, Parker et al.; Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; Sorlie, Tibshirani 
et al. 2003; Hu, Fan et al. 2006; Parker, Mullins et al. 2009).  For many cancers, improper 
maintenance of genome stability is a major process in tumorigenesis and the 
characterization of the tumor genomic DNA landscape is an important avenue for 
oncogenic investigation (Pinkel and Albertson 2005).  Array comparative genome 
hybridization (aCGH) studies of tumor copy number states have demonstrated that 
tumors with similar gene expression subtypes may also share similar DNA Copy Number 
Aberrations (CNA) (Russnes, Vollan et al.; Bergamaschi, Kim et al. 2006; Chin, DeVries 
et al. 2006; Wood, Parsons et al. 2007; Van Loo, Nordgard et al. 2010).  In some cases, 
tumors have single gene-specific amplicons occurring in a large percentage of cases, such 
as amplification of ERBB2 in 30% of Breast tumors (Kauraniemi, Hautaniemi et al. 
2004).  In these cases, treatment options blocking the aberrant gene offer positive 
response (i.e. trastuzumab(Goldenberg 1999; Burris 2001)).  However the inherent 
heterogeneity of tumors is likely to demonstrate that the biological impact of several 
distinct CNA events initiates tumorigenesis through disruption of genes in multiple 
pathways.   
Nowhere is the case of genomic instability-driven tumorigenesis more prevalent 
than in the Basal-like subtype, where the majority of its tumor genome exhibits aberrant 
copy number states (Ding, Ellis et al.; Russnes, Vollan et al.; Bergamaschi, Kim et al. 
2006; Chin, DeVries et al. 2006; Van Loo, Nordgard et al. 2010). Identifying genes that 
contribute to this instability phenotype could be useful not only from a biological 
perspective, but also possibly as a clinical predictor of response to therapy. 
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In this study we sought to specifically search for CNA that are correlated with 
specific gene expression subtypes, and to determine if  these events explain some of the 
phenotypic characteristics of a given tumor subtype.  Through combined gene expression 
and DNA copy number analyses, we identified numerous CNA associated with Basal-like 
tumors, including the unique loss of a region on 5q that harbors many DNA repair genes. 
Loss of this region is associated with loss of common tumor suppressor genes, highly 
aberrant copy number profiles and a potential increased sensitivity to DNA-damaging 
agents.  
 
MATERIALS AND METHODS 
Datasets 
Three separate patient sets were used in this study, each of which contained gene 
expression and DNA copy number microarray data. We combined 2 into a single training 
set so that we could have maximum statistical power to detect subtype-specific copy 
number events. The combined training set included one data set consisting of breast 
tumors obtained from the United States (called USA) and the second were tumors from 
Norway (called “NW”). The third data set (called “BORG”) was used as a 
validation/testing set.  All samples were collected using IRB approved protocols and all 
patients signed informed consent forms.  
For the USA data set, all tumors were assayed for gene expression patterns using 
Agilent DNA microarrays, and a subset of tumors were assayed for copy number changes 
using Infinium Human-1 109K BeadChip (Illumina, San Diego, CA, USA). For gene 
expression, our USA cohort contained 337 human breast tumors (USA337), which was 
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largely taken from Prat et al 2010 and that consisted of 275 samples from primary sites, 
35 from sites of metastasis, and 14 normal tissues. Log2 Ratio data was taken from the 
UNC Microarray Database (UMD), filtering for a lowess normalized value of 10 or 
above to each channel.  Data is available from Gene Expression Omnibus under series 
GSE10893.  
The Norway/NW data set consists of 103 previously published breast tumors 
assayed on custom Agilent Microarrays for gene expression (GSE3985), and for copy 
number changes using Infinium Human-1 109K BeadChip (Naume, Zhao et al. 2007; 
Nordgard, Johansen et al. 2008). The BORG dataset consists of 359 breast tumors 
assayed using custom produced oligonucleotide microarrays for gene expression, BAC 
microarrays for copy number, and which has been previously published (Jonsson, Staaf et 
al.) in GEO under series GSE22133. 
 
Classifying tumors for expression-based subtype classification 
 The Lowess normalized R/G Log2 ratio data from the USA337, NW103 and 
BORG359 were used and median centered independently within each data set, prior to 
collapsing (via averaging) from probes to HGNC gene symbols.  Datasets were then 
limited to the gene symbols shared across them.  After column standardization of both 
datasets (samples at N(0,1)), Distance Weighted Discrimination (DWD) (Benito, Parker 
et al. 2004) was used  to remove platform bias prior to classification.  The  PAM50 gene 
set predictor (Parker, Mullins et al. 2009) in conjunction with a newly identified Claudin-
low predictor (Prat, Parker et al.) were used to assign subtypes to the tumors in these 
three datasets.  
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 Assessment of tumor genomic DNA copy number changes 
77 USA and 103 NW samples that had blood/normal and tumor DNA pairs were 
each assayed using the Infinium Human-1 109K BeadChip (Illumina, San Diego, CA, 
USA), with an average resolution of 1 probe per 26kb (median of 1 probe per 13kb).  
Each sample was labeled, hybridized, scanned and analyzed according to the 
manufacturer’s protocol (Gunderson, Steemers et al. 2005). To account for germline 
specific copy number polymorphisms, a pool of 118 blood-drawn DNA samples was 
compiled and used as Illumina’s standard clustering reference through the BeadStudio 
software, which estimates allele-specific intensity boundaries.  Genotype reports and 
LogR values were extracted with reference to dbSNP's (build 125) forward allele 
orientation using BeadStudio (v3.1, Illumina, San Diego, Ca, USA).  Sample values can 
be found on GEO under series GSE10893, platform GPL8139. 
 
Identification of CNA with SWITCHdna 
 To determine regions of copy number aberration (CNA), we developed a new 
analysis method that is a modification of the SupWald method (Andrews 1993; Bai 
1998), where we created an R suite of functions called “SWITCHdna”, to identify 
breakpoints in aCGH data.  Statistical problems in aCGH analysis are the detection of 
transition points (positions where DNA copy numbers change) along with identifying 
most-likely false positive candidates. In SWITCHdna, the estimation of number of 
transition points (K) is performed sequentially. First, we test for the presence of at least 
one transition point (versus none) across the entire chromosome. If the test shows no 
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significant deviation from the null model (or no change points) we accept K=0. 
Otherwise, we find the change point that maximizes the F statistic and continue and test 
for the presence of the two change points (versus one) and so on.  We accepted a change 
point when the minimum of two criteria were met: 1) size of region on either side of the 
breakpoint was larger than α (number of observations (in our case, array probes) which 
would cover user-defined range) and 2) the F statistic of each segment was the maximum 
value possible and above the user-specified threshold.  Following detection of the 
transition points, a segment average value and corresponding z-score, are determined 
along with the number of observations used.   
A significance filter was applied to the raw SWITCHdna-identified segments in 
order to reduce noise and increase the probability of identifying biologically relevant 
regions.  To determine this significance cutoff, we created 100 permuted datasets from 
our LogR ratio values, which had values shuffled within the space of each chromosome.  
SWITCHdna was then run on each of these permuted datasets to gather information 
about random segment statistics.  We found that a z-score of 3 or greater, and intensity 
cutoff of 0.1 was sufficient to select for values with a Family-Wise Error Rate (FWER) of 
5% (data provided on website).   All subsequent plots and tables were produced after 
applying this significance filter to our data.  Plotting functions (plot.freq.SW) display the 
prevalence of subtype-shared CNAs in genome-space.  SWITCHdna is a provided as a 
source script in R (R Development Core Team 2009) and  available for download at: 
https://genome.unc.edu/pubsup/SWITCHdna/. 
 
Determining subtype-specific CNAs 
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 Using the cnaGENE function of SWITCHdna, the segment output file was 
converted into an indicator matrix, where for each sample, each gene’s copy state was 
represented as -1 = loss, 0 = no change, 1 = gain.  All probes within the boundaries for a 
gene were summarized through weighted voting.  In cases where there was conflicting 
copy status for a gene, the gene was given status zero.  For each subtype, the counts of 
gains and losses were compared versus all other samples in order to identify subtype-
specific CNAs.  A Fisher’s Exact test was performed on the subtype vs. rest counts for 
each gene.  Genes with p-values < 0.0001 were then gathered for each subtype.  The 
same strategy was performed via collapsing data within each cytoband except that the 
copy status for cytoband was determined by a voting schema.  First, the subtype-specific 
cytobands were identified and the regions within the cytobands of localized CNA were 
determined by the significant genes found within each cytoband, allowing for more 
separation of CNA loci (Appendix IVB). 
 
RNAi Cell Line experiments 
Stable RNAi knockdown lines were generated from hTERT-immortalized, human 
mammary epithelial cell lines (HME-CC) cultured as described in Troester et al 
(Troester, Herschkowitz et al. 2006).  Genes were targeted with shRNA constructs for 
RAP80/UIMC1, RAD50 (Origene) and RAD17 (Oligoengine) (RAP80:  TI328027 
CCTAG-ACCTCCTTCTCTGATCCAGAATGA; RAD50: TI308519 – 
CTTCAGACAGGATTCTTG-AACTGGACCAG; RAD17 - 
UGCCAUACCUUGCUCUACU) and control lines were concurrently made using a non 
effective construct (Origene – TR30003, Oligoengine – VEC-PRT-0006). 10ug of each 
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vector was transfected into Phoenix 293T cells using Lipofectamine 2000 (Invitrogen) as 
per manufacturer’s instructions to produce retrovirus. Viral supernatant was collected and 
applied to the HMEC line with 75ug of polybrene.  Stable populations were selected by 
culturing in 1ug /mL puromycin for the RAD50 and RAP80 knockdown lines and vector 
matched control, or 400ug /mL geneticin for the RAD17 knockdown line and its control. 
 
Western Blot Analysis 
Cells were grown in 10-cm tissue culture-treated dishes to 80% confluence and 
then harvested, protein isolated, and quantified as described previously (Troester, 
Hoadley et al. 2004).  Membranes were probed for RAD17 (AB3261; Millipore, 
Billerica, MA, USA), RAD50 (#3427; Cell Signaling Technology, Danvers, MA, USA), 
and alpha-tubulin (sc-9104, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 
followed by anti-rabbit or anti-goat IgG horseradish peroxidase-linked whole antibody 
(sc-2020; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA or Amersham 
Biosciences, Piscataway, NJ USA) and detected using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). 
 
Cell Cytotoxicity Assays 
Sensitivity to drugs was assessed by a modified mitochondrial dye-conversion assay (Cell 
Titer 96, Promega #G4100, Madison, WI, USA) as described (Troester, Hoadley et al. 
2004; Hoadley, Weigman et al. 2007).  Carboplatin and paclitaxel were purchased from 
UNC Hospital Pharmacy (Chapel Hill, NC, USA).  72h inhibitory concentrations that 
caused a 50% reduction in MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
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bromide) dye conversion (IC50) was determined using nonlinear regression (Van Ewijk 
and Hoekstra 1993). 
 
Survival Analysis 
A mean expression value for RAD17+RAD50, and INPP4B, for each patient in 
the USA337 and NKI295 (van de Vijver, He et al. 2002) datasets was determined and 
patients were rank-ordered and separated into three equal groups representing low, 
medium, and high average expression for each gene or combined genes (Appendix IVA). 
Survival analyses were performed using the Kaplan-Meier test in R. 
 
RESULTS 
Identifying Subtype-Specific Regions of Copy Number Aberration 
 There have been many studies of copy number changes performed on human 
breast tumors, with previous studies identifying numerous  regions of loss and gain 
(Jonsson, Staaf et al.; Bergamaschi, Kim et al. 2006; Chin, DeVries et al. 2006; 
Fridlyand, Snijders et al. 2006; Haverty, Fridlyand et al. 2008) . Most of these studies, 
however, did not specifically search for regions uniquely associated with specific 
intrinsic subtypes of breast tumors (Prat, Parker et al.; Perou, Sorlie et al. 2000; Sorlie, 
Perou et al. 2001; Sorlie, Tibshirani et al. 2003; Hu, Fan et al. 2006; Parker, Mullins et al. 
2009). We explicitly searched for these subtype specific DNA copy number aberrations 
using a data set of 180 tumors with Agilent gene expression and Illumina 109,000 SNP 
marker copy number data. We first classified tumors into one of each of the six 
predefined subtypes (Prat, Parker et al.; Parker, Mullins et al. 2009).  To identify regions 
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of copy number gain/loss, we developed a new segmenting method called “SWITCHdna” 
(Sup Wald IdenTification of copy CHanges in dna).   The SWITCHdna method involves 
two main parts: 1) transition point identification, and 2) segment significance testing via 
permutation analysis; specifics of the SWITCHdna method can be found in the Methods 
and at https://genome.unc.edu/pubsup/SWITCHdna/.   
SWITCHdna identified copy number gains and losses in each tumor, which were 
then aggregated based on subtype membership to look at the frequency of each copy 
number change in each subtype (plot.freq.SW).  CNA landscape frequency plots, and the 
regions specific to each subtype (Appendix IVA) for each tumor subtype are shown in 
Figure 4.1. Overall the subtype frequency plots recapitulate previous findings:  Basal-like 
tumors clearly show the most copy number changes (Bergamaschi, Kim et al. 2006), 
Luminal A tumors show gain of 1q and loss of 16q (Chin, DeVries et al. 2006), and the 
HER2-enriched subtype shows frequent gains of 17q22 (Bergamaschi, Kim et al. 2006), 
which harbors HER2/ERBB2. A number of new findings were seen here including the 
first aCGH characterization of the Claudin-low subtype, which despite its high grade 
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 Figure 4.1 
Figure 4.1. Copy number landscapes for human breast cancer intrinsic subtypes.  Subtype frequency 
plots from SWITCHdna show regions of copy number aberrations shared by members of the same subtype.  
Grey shading indicates regions of change with regions below the center representing losses, and shading 
above the line indicates gains. Regions in dark black were statistically associated with a particular subtype.  
A) copy number landscape of all 180 tumors, B) Basal-like, C) Claudin-low, D) HER2-enriched, E) 
Luminal A, and F) Luminal B. 
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and similarity to Basal-like tumors, shows very few copy number changes; an ER-
negative and copy number neutral tumor subtype has been previously reported (Chin, 
Teschendorff et al. 2007).  
When we searched for subtype-specific copy number events using cytoband 
defined regions (identified in Figure 4.1 by black shading), the Basal-like subtype stood 
out as clearly showing the most subtype-specific events (Figure 4.1B), and therefore, for 
the remainder of this paper we will focus on a few of these Basal-like genetic events. A 
number of regions associated with Basal-like tumors were identified including a 
previously described amplicon on 10p (Ding, Ellis et al.),  and a region of deletion on 4q 
(Figure 4.2) that contains the gene INPP4B that was recently identified as a potential 
tumor suppressor involved in inhibition of PI3K signaling (Gewinner, Wang et al. 2009). 
We also observed a previously described 16q loss (Haverty, Fridlyand et al. 2008), and 
deletion on 5q11-35 (Bergamaschi, Kim et al. 2006).  
 As would be expected, when we searched the data by gene (as opposed to by 
cytoband) we saw high aberration rates in Basal-like specific regions identified from 
SWITCHdna, including frequent amplification of the 10p genes MAP3K8, ZEB1, and 
FAM107B, and frequent deletion of genes on 5q (Table 4.1a). As has been reported 
before, Basal-like cancers also show frequent amplification of c-MYC (Grushko, Dignam 
et al. 2004), and KRAS (Hoadley, Weigman et al. 2007), and much less frequent 
amplification of HER2 that was the most frequent within the HER2-enriched subtype; 
also these analyses recapitulate previous findings of  loss/LOH of RB1 (Herschkowitz, 
He et al. 2008) and TP53 were common (but not unique) in Basal-like tumors.   
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 Table 4.1 
Table 4.1. Frequency of copy number aberrations according to intrinsic subtype.  A) Data for the 
USA-Norway combined dataset for deletions, amplifications, and co-occurrence.  Values are presented in 
‘Count (%)’ format.  Specific counts are given for individual deletions or co-deletions, with each sample 
only classified into one category. Counts for average gains/losses for each subtype were created by 
averaging counts from the discrete aberration matrix made by the cnaGENE function of SWITCHdna for 
each sample within a given subtype. Total number of aberrations is the sum of gain and losses. Rates of co-
occurrence of 5q cluster loss with other genes are shown.  N refers to the number of total samples with 5q 
loss.  Fisher’s exact tests or Chi-square approximations were done to determine if the rates of occurrence or 
co-occurrence were at significant levels.  B) The same data is shown for the BORG359 dataset for 
comparison (Jonsson, Staaf et al.). 
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 Figure 4.2 
Figure 4.2. Basal-like copy number landscape with highlighted regions.  Subtype frequency plot 
focusing of the Basal-like group showing the location of RAD17, RAD50, and RAP80 on the 5q arm 
(highlighted by red bar).  INPP4B, MAP3K8, FAM107B, and ZEB1, each of which falls into other Basal-
like regions of copy number change, are also highlighted in red.  The locations of BRCA1, BRCA2, PTEN, 
RB1, and TP53, genes that were frequently, but not specifically, lost in the Basal-like subtype are 
highlighted in purple. 
 
Basal-like tumors have previously been observed to have copy number loss and downr-
egulation of genes involved in BRCA1 DNA damage repair (Natrajan, Weigelt et al.).   
Loss at 5q11.1-5q35.3 is notable for containing several genes involved in the 
BRCA1-dependent DNA repair pathway including RAD17, RAD50, and RAP80.  
BRCA1 has already been linked to Basal-like tumors where it is known that BRCA1 
mutation carriers develop Basal-like tumors 80-90% of the time they develop breast 
cancer (Foulkes, Stefansson et al. 2003; Sorlie, Tibshirani et al. 2003; Arnes, Brunet et al. 
2005); however, in most sporadic Basal-like tumors (like those studied here), the BRCA1 
gene is normal (Richardson, Wang et al. 2006), and thus it is possible that loss of 5q may 
“phenocopy” loss of BRCA1. Closer examination of the pattern of loss of genes on 5q 
revealed that each gene was rarely lost as an individual event, but predominantly as a pair 
or triplet of loss (Table 4.1a).  In addition, these doublet or triplet losses occur at the 
 
 
122
highest rates in the Basal-like subtype, but did also occur much less frequently in the 
HER2-enriched subtype.  Loss of the 5q segment was also found to frequently co-occur 
with loss, or amplification, of other  cancer-associated regions; for example the 10p 
amplicon identified by SWITCHdna was statistically associated with 5q loss, as was loss 
of the RB1 (~80%), PTEN, BRCA1, and TP53 genes (Table 4.1a).  Furthermore, 
significantly lower RNA expression of RB1, PTEN, or BRCA1 was observed in tumors 
that had copy number loss of these genes by SNP assay. 
In order to validate the findings observed in the USA+NW 180 tumor combined 
dataset, we classified the samples in Jonsson et al. (Jonsson, Staaf et al.) (BORG) 
according to PAM50 and Claudin-low subtype, and performed similar supervised 
analyses using their BAC copy number data; very similar associations between CNA and 
subtypes were seen (Table 4.1b).  Lastly, in Jonsson et al., they identified 6 unique tumor 
subtypes using copy number landscapes, which we determined were also highly 
correlated with our expression defined subtypes (p-value < 0.001, Appendix IVC); 
importantly, there was high overlap between our Basal-like subtype and their Basal-
Complex phenotype, and both showed the most frequent loss of 5q and gain of 10p. 
 
Increased Genomic Instability of Tumors Associated with Loss of Specific 
Regions/Genes 
In order to objectively assess “genomic instability”, we simply calculated a 
loss/normal/gain value for each gene, thus providing ~22000 measurements per tumor. 
We examined the levels of genomic instability by subtypes using the average number of 
gains/losses; the total number of alterations was then determined by adding together the 
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number of losses and gains. As expected, the Basal-like subtype was by far the most 
prone to gains and losses, while the Luminal A group most consistently showed the 
lowest number of events (Table 4.1a and 4.1b).  We also found that copy number 
aberrations in specific genes were associated with significantly higher numbers of 
changes.  For example, tumors with loss of PTEN, RB1, or TP53, or amplification of a 
Basal-like associated 10q region were found to have higher rates of copy number 
aberrations compared to their non-aberrant counterparts (Table 4.2).  Loss of genes in the 
5q cluster was also highly associated with higher numbers of gains and losses, with 
greatest instability seen with loss of all three genes. 
 
Low expression of some genes residing in Basal-like regions correlates with poor 
survival and predicts therapeutic response 
mRNA Expression analysis of RAD17, RAD50, RAP80, INPP4B, PTEN, and 
RB1 in the USA337 data set showed that their expression was lowest in the Basal-like. 
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 Table 4.2 
Table 4.2. Association of specific copy number aberrations and increased genomic instability.  The 
average numbers of CNAs for gains, losses, or both, are shown for the entire dataset and within sets of 
tumors with a given copy number alteration (5q, PTEN, RB1, TP53 and 10p).  A Wilcoxon-rank sum test 
was performed to see if the rate of copy number aberration between each group (Pair-wise:  Aberration vs. 
Other, or No Aberration) was significantly different (*). 
 
subtype, thus mirroring their copy number status (Figure 4.3, Figure 4.4).  We also 
examined these genes in the Basal-like and Luminal A subtypes in the context of the 
BRCA1-depedent Repair Pathway (Figure 4.4) and found that the Basal-like subtype 
exhibited a profile much more consistent with dysfunctional DNA repair.  Using patient 
survival data from the USA337 and NKI295 datasets, Kaplan-Meier analysis was done to 
examine if there were differences in outcomes based on differential expression of these 
genes.  We found that those patients with the lowest average expression of 
RAD17+RAD50 had worse outcomes when compared to high expression (Supplemental 
Fig 1).  A similar trend was observed with INPP4B, mirroring previously observed 
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results (Gewinner, Wang et al. 2009).  RAD17+RAD50 expression was also examined in 
the Hess et al. 2006 dataset, which examined T/FAC neoadjuvant chemotherapy 
responsiveness across 130 patients (Hess, Anderson et al. 2006); low expression of 
RAD17+RAD50 was correlated with pCR vs. not (p-value of ANOVA = >0.00001).  
This finding may be due to the association between low expression of RAD17+RAD50 
and Basal-like tumors, as Basal-like tumors have also been shown to have high 
neoadjuvant chemotherapy response rates (Rouzier, Perou et al. 2005; Carey, Dees et al. 
2007). 
 
Knockdown of RAD17 with or without RAD50 affects sensitivity to 
chemotherapeutics 
Given the involvement of RAD17, RAD50 and RAP80 in the BRCA1-dependent 
DNA repair pathway, we wanted to determine whether disruption of this pathway by 
gene knockdown would lead to increased chemotherapeutic sensitivity, in particular, 
sensitivity to those drugs whose mechanism of action has already been shown to be  
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 Figure 4.3 
Figure 4.3. Analysis of the relative mRNA expression levels of individual genes according to intrinsic 
subtype. Box plots for individual genes determined using the USA337 sample set. P-values were 
determined by 2-way ANOVA.  A) RAD17, B) RAD50, C) RAP80, D) PTEN, E) RB1, and F) INPP4B 
 
linked to sensitivity based upon BRCA1 loss.  At least two such drugs that exist that are 
carboplatin/cisplatin (Chang, Glaspy et al.; Silver, Richardson et al.) and PARP inhibitors 
(Donawho, Luo et al. 2007; Fong, Boss et al. 2009).  We began with RAD17 because it 
was the most frequently lost of the three genes and involved in every double and triple 
loss instance.  RAD17 was stably knocked down with shRNA in the HME-CC (hTERT 
immortalized Human Mammary Epithelial Cell) (Troester, Hoadley et al. 2004) line and 
knockdown was confirmed by Western blotting (Figure 4.5a). The knockdown line, or 
control cells targeted with an off-target GFP construct, were treated with ABT-888 
(PARP inhibitor), carboplatin, or paclitaxel.  HME-CC cells with RAD17 knock down  
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Figure 4.4. 
Figure 4.4. Visualization of the DNA-repair pathway colored according to copy number and gene 
expression values.  A) Basal-like cancers, and B) Luminal A cancer average subtype profile is shown, as 
visualized using Cytoscape (2.6.1) (Shannon, Markiel et al. 2003).  Stars denote the 3 co-lost genes 
(RAD17, RAD50, RAP80).  Log2 normalized intensity values were used for expression data (small circles) 
and for copy number values (rounded squares).  Grey nodes values lost after filtering.  Intensity values 
were scaled to be within bounds from -2 to 2, displayed by the color bar.  Background circles denote 
genes/proteins that typically function within specific functional complexes. 
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exhibited increased sensitivity to ABT-888 (IC50 for RAD17 knockdown versus control:  
262.2 uM versus 296.3 uM) and carboplatin (IC50 for RAD17 knockdown versus control:  
29.6 uM versus 43.3 uM).  No difference in paclitaxel sensitivity was observed, which 
was used as a non-DNA damaging agent control (IC50 for RAD17 knockdown versus 
control:  2.9 nM versus 3.0 nM) (Figure 4.5b).  A RAD50 knockdown line was generated 
and did not exhibit any change in sensitivity to ABT-888 (IC50 for RAD50 knockdown 
versus control:  205.7 uM versus 191.7 uM) and had a paradoxical decrease in sensitivity 
to carboplatin (IC50 for RAD50 knockdown versus control:  25.9 uM versus 14.0 uM).  
We emulated the co-occurring loss we observed in the breast tumors by generating a 
double knockdown line of RAD17 and RAD50, which showed a more pronounced 
sensitivity to ABT-888 (IC50 for Double knockdown versus control:  142.4 uM versus 
244.2 uM) and carboplatin (IC50 for Double knockdown versus control:  17.3 uM versus 
31.7 uM). 
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 Figure 4.5 
Figure 4.5. Effects of Knockdown of 5q DNA-repair pathway genes.  A) Western blots showing 
knockdown of RAD17 and RAD50 in single, or double, RNAi knockdown lines.  KD refers to the 
knockdown line and C refers to the control line (vector control).  Tubulin staining was performed as a 
loading control.  B) Estimated IC50 with 95% CI for ABT-888, Carboplatin, and Paclitaxel for each 
knockdown line and respective control based on mitochondrial dye-conversion assay. 
 
DISCUSSION 
 The presence of subtypes of breast cancer identified using gene expression 
patterns suggests that distinct underlying genetic events may be driving each disease 
type. To determine if this is true for the intrinsic subtypes of breast cancer, we first 
classified 180 diverse tumors according to gene expression subtype, and then performed 
supervised analyses of their tumor DNA copy number landscape to determine if subtype-
specific copy number events exist. We identified many such regions, and then validated 
those findings on a third, independent dataset. The most obvious findings were that the 
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Basal-like subtype showed by far, the greatest number of subtype specific CNA (Figure 
4.1B)  and they were also the most genomically unstable as determined by the sheer 
number of copy number events. In addition, one of these Basal-like subtype enriched 
events losses (i.e. 5q) many genes involved in DNA repair, which may serve as a 
biomarker of responsiveness to DNA damaging agents. 
The 5q region loss in Basal-like patients may help explain why despite many 
patients having normal BRCA1 (Richardson, Wang et al. 2006), high levels of genomic 
instability and a “BRCAness” phenotype are observed in most Basal-like Breast Cancers.  
Our hypothesis is that loss of RAD17, RAD50 and/or RAP80 leads to impaired BRCA1 
function, impaired homologous recombination mediated DNA repair, and over time, wide 
spread genomic instability with significant aneuploidy.  The copy number states of 
RAD17, RAD50, and RAP80 are also reflected in their expression levels, which is also 
mirrored by similar DNA losses and low expression for other important genes including  
INPP4B on 4q (Gewinner, Wang et al. 2009), PTEN on 10q (Saal, Johansson et al. 2007) 
and RB1 on 13q (Herschkowitz, He et al. 2008).  However, there are two caveats to these 
analyses and hypothesis.  First, the 5q loss is a large loss and typically involves >100 
genes, thus we cannot definitively say that loss of these 3 genes are the targets of this 
deletion.  Second, a high frequency of co-occurring other region DNA losses happens in 
tumors with 5q loss; for example, in ~80% of tumors with 5q loss, RB1 DNA loss also 
occurs (and by itself is also associated with increased genomic instability).  
In addition, 5q loss is also statistically correlated with TP53 loss (Table 4.2, 
~60%), thus Basal-like cancer typically loses some combination of 5q, RB1 and TP53. 
Given the high occurrence of chromosome losses of regions that are not physically 
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linked, it is impossible to say which one is the cause of the genomic instability, however, 
a more reasonable hypothesis is that each of these regions harbors genes needed for 
proper maintenance of the genome, and that they tend to be lost together in Basal-like 
cancers, and that the loss of 2-3 of these regions causes the genomic instability and high 
aneuploidy seen in Basal-like cancers in this study, and others (Jonsson, Staaf et al.; 
Russnes, Vollan et al.; Bergamaschi, Kim et al. 2006; Chin, DeVries et al. 2006). 
A number of findings do argue in favor of these 3 genes (RAD17, RAD50, and RAP80) 
as being targets of this deletion, whose loss leads to genomic instability. First, the fact 
that single gene loss is infrequently observed while double and triple gene loss 
predominate indicates that these genes need to be lost in a coordinated manner; if loss of 
one of these genes was sufficient to cause disease, then these genes would have been 
cloned years ago as classic tumor suppressors similar to BRCA1, however, if loss of 2 or 
3 is needed to show the phenotype, then only larger deletions would be able to create this 
effect.  
Data mined from yeast genome and fitness databases also shows that knockout of 
the homologues of RAD17 or RAD50 conferred sensitivity to a number of DNA-
damaging agents including bleomycin, carboplatin, cisplatin, mechlorethamine, and 
camptothecin (http://fitdb.stanford.edu/).  Using our knockdown RAD17 cell line, we 
observed increased sensitivity towards treatment with a PARP inhibitor or carboplatin 
(Figure 4.5b).  When we performed the same experiment in RAD50, we did not observe 
the same increase in sensitivity to these agents, and in fact saw a paradoxical decrease in 
sensitivity to carboplatin, however, a double knockdown line of RAD17 and RAD50 
showed increased sensitivity compared to the RAD17 single knockdown line alone, 
 
 
132
which suggests that RAD50 disruption may need to be coupled with RAD17 disruption to 
have an observable phenotype; do note on Table 4.2 that single losses of RAD50 were 
rare, and that the most common 5q loss was loss of RAD17+RAD50+RAP80 and next in 
frequency was loss of RAD17+RAD50; this too is consistent with the need to remove 
more than one gene in vivo to see an effect. 
These Basal-like and copy number findings also have important clinical 
implications. Foremost is that if 5q loss results in impaired BRCA1-pathway/homologous 
recombination DNA repair, then the loss of this region may sensitize tumors to specific 
classes of DNA damaging agents. Based upon BRCA1 in vitro (Quinn, Kennedy et al. 
2003; Farmer, McCabe et al. 2005) and in vivo (Silver, Richardson et al.; Donawho, Luo 
et al. 2007)studies, these drugs would include PARP inhibitors and the platins 
(cisplatin/carboplatin); thus, loss of RAD17-RAD50-RAP80 (as assessed by mRNA 
and/or genomic DNA) may be a biomarkers of response, which could be performed 
retrospectively or prospectively. Second, the co-occurrence of 5q, RB1, and TP53 loss 
are likely causative events in Basal-like carcinogenesis (which is corroborated by mouse 
studies) (Cressman, Backlund et al. 1999; Herschkowitz, Simin et al. 2007; Jiang, Deng 
et al. 2010) and we hypothesize that it is the loss of these DNA repair genes, and cell 
cycle checkpoint genes that causes the high proliferation rates and aggressive outcomes 
seen in most Basal-like cancers. Thus, our integrated studies of gene expression and copy 
number has identified important pathway-based determinants of Basal-like cancers and 
identified a possible therapeutic biomarker. 
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CHAPTER V 
CONCLUSION 
 
The interest in breast cancer stems from the fact that it is the leading cause of cancer 
deaths in women 20 to 59 (Jemal, Murray et al. 2005) and that the number of survivors is 
growing.  The fundamental purpose of this work is to provide an increased understanding of 
tumor subtype etiology (particularly the Basal-like subtype), and to provide a new set of analysis 
tools, the combination of which is being used to develop and guide personalized medicine.  Our 
approach utilizes at least two powerful genomic technologies, namely DNA microarrays to assay 
for gene expression patterns, and to assay for genomic DNA copy number events. The chapters 
of this thesis are laid out based on granularity of focus, the first of which focused on a single 
growth regulatory pathway (i.e. EGFR).  By using the expression profiles of cell lines and 
tumors, EGFR-inhibitors were evaluated and shown to have a strong link to a decrease of cell 
proliferation in basal-like samples.  This was identified through observations of subtype-specific 
expression differences in the EGFR-RAS-MEK pathway along with related prognostic 
significance.  Second, the power of subtype identification aids in treatment assignment, however 
subtype identification methods are not so clear cut, therefore, we developed an automatic, 
statistically rigorous method for the identification of important gene-sample relationships. Third, 
we see that the underlying genomic landscape of DNA copy is also preserved in tumor subtypes, 
which aids in the identification of specific oncogenic targets previously missed in gene 
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expression studies.  Given that previous work in identifying DNA copy changes relied on low-
resolution assays and Z-score based methods, we developed a user-friendly method that is 
compatible with complex high data content data sets, to not only identify these copy events but 
evaluate their association to subtype.  In summary, the growth of genomic data is providing 
exciting new data and advances in tumor characterization and treatment, but only when well-
defined by statistically rigorous methods that can be used by the community. 
In most breast tumor cases, there is a prescribed set of treatment options, provided tumors 
fall into specific categories (ER+ staining would suggest hormone therapy and HER2+ would 
suggest supplemental Trastuzamab).  Other factors that guide therapeutic decision making 
include node status, age, tumor size, and histologic grade (Clark 2001; Goldhirsch, Wood et al. 
2003).  By focusing on specific pathway-by-subtype interactions in Chapter 2, namely EGFR 
pathway within Basal-like cancers, a cell line model that was sensitive to EGFR, MEK and PI3K 
was analyzed and three major expression clusters were identified that were found to differ across 
other cell lines and tumor subtypes.  This pathway signature gives marked improvement over 
single gene markers because while 50% of all basal-like tumors had high expression of EGFR, 
95% had the EGFR pathway activation signature (Hoadley, Weigman et al. 2007), thus 
suggesting possible downstream activation events in this pathway in many Basal-like tumors. 
This pathway signature can then be used as a consistent specific marker for Basal tumors which 
may be used to guide patients to anti-EGFR treatment containing regimens (i.e. cetuximab), 
which is currently being tested through retrospective analysis of existing randomized trial 
cohorts. 
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The utilization of gene expression microarrays for the classification of breast tumors has 
significantly improved the array of factors one can use to determine tumor etiology.  The original 
identification of the 4 subtypes (Perou, Sorlie et al. 2000) has been seen in several other breast 
cancer studies, lending weight to its repeatability and robustness (Sorlie, Perou et al. 2001; van 't 
Veer, Dai et al. 2002; Sotiriou, Neo et al. 2003; Ma, Wang et al. 2004).  These studies not only 
showed gene expression patterns that illuminate differing biochemical processes within the 
tumor but also demonstrated prognostic value related to survivability as well as tumor 
recurrence.   
It was demonstrated in Chapter 3 that while these studies are quite informative, they lead 
themselves to bias by investigators who use node selection of dendrograms to select gene sets to 
run these analyses.  This occurs due to the fact that independent row-column clustering (IRCC), 
such as hierarchical clustering, is mainly used to identify sample groupings and relies on 
correlation, a global metric, to determine association.  The fact is that IRCC limits the utility of 
gene expression datasets in that a gene can have different correlated partners in sample sets due 
to the different roles across tumors, and thus if a gene is correlated with two different gene sets, 
IRCC only puts it into one set.  By utilizing correlations in gene and sample space, IRCC 
methods hold these gene expression patterns to only 1 sample set and 1 sample belonging to only 
one group.  Given the heterogeneous nature of these tumors, this approach is not sound and is 
something that LAS directly addresses because a given gene or sample can belong to more than 
one cluster.  It also has the ability to increase the number of genes in a genelist and samples in a 
sample set due to the application of its scoring function, thus, this could and should be a widely 
used tool for gene expression space investigations. LAS/bi-clustering was proven to be robust in 
real biological applications because it was able to recapitulate the subtypes of 2 different tumor 
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gene expression datasets, one breast (Hu, Fan et al. 2006) and one lung (Bhattacharjee, Richards 
et al. 2001),  with no prior knowledge (Shabalin, Weigman et al. 2009).  LAS’s easy to use GUI, 
rapid computational time, and adaptable output makes it straightforward to be easily adapted to 
transform gene expression datasets into gene/sample relationships which can be more 
confidently investigated. 
 As previously discussed, changes in tumor genomic DNA are important cancer causing 
events, and events that we strove to study and incorporate into a more complete portrait of tumor 
biology. Analyses using aCGH platforms have shown that tumor subtypes can have shared 
CNAs, along with their expression profiles.  The low resolution of early platforms (one 
measurement every 1-10Mb) combined with non-ideal algorithms still identified breast tumor-
specific regions of CNAs, but they were large and few were subtype-specific (Richard, Pacyna 
Gengelbach et al. 2000; Iafrate 2004; Loo, Grove et al. 2004).  While the availability of tools to 
analyze this data grew, they were hard to use, and very computationally slow (Hupé, Stransky et 
al. 2004; Olshen, Venkatraman et al. 2004).  This made analysis difficult to do and with the 
increased resolution of SNP platforms making the number of markers 10-20x greater, the 
analysis time became cumbersome and there was no way to visualize the data for so many 
probes. 
 These features were the driving force behind the development of SWITCHdna, which is 
an R package that can be easily and quickly run.  While speed is one of the main improvements 
of SWITCH over other methods (for the data provided in Chapter 4, it performed up to an order 
of magnitude faster than CBS (unpublished results, SWITCHdna supplement), it is also 
statistically robust.  The core function of SWITCHdna is an adaptation of the SupWald method, 
  
143
traditionally used to find the largest change rates in economic data (Andrews 1993) and has had 
much work leading to its optimization.  Like other methods, it allows the user to adjust potential 
segment minimum sizes and test thresholds for passing (F test in this case).  Regarding 
performance of segment identification, SWITCHdna was able to find CNAs of a few hundred kb 
in size, and even smaller on higher resolution platforms (Illumina 610k, data unpublished).  This 
is very important for identifying more precise boundaries of CNAs so that genes aren’t miss-
represented as gained or lost if they are not. 
 The second main focus of SWITCHdna really demonstrates its broad application for 
biological interpretation.  Before any kind of graphing or gene summarizations, a second round 
of statistical filtering is applied.  Even though you can adjust initial filtering to limit peaks, 
mainly by increasing the F statistic threshold, it is still possible that certain segments are not 
statistically significant and landscape plots (like that in Figure 4.1) are noisy.  To adjust for this, 
there is a second round of filtering which uses the Z-score and average intensities of the SNPs to 
mainly eliminate low-intensity segments, which may generate large F statistics, but actually 
represent no copy change.  This step is one of the main differences between SWITCHdna and 
other methods which lead to its improved repeatability across datasets and the better refinement 
of peak boundaries prior to any additional analysis.  The accessory functions in SWITCHdna 
directly led to the findings outlined in Chapter 4 by providing statistical support for counting 
specific CNA events in each of the subtypes so that we could strongly associate gains and losses 
to subtypes, a process not previously performed in other studies. 
 Chapter 4 represents the aggregation of genomic data to not only describe new 
biomarkers for Basal-like cancers, but can also identify gene aberrations that are most likely 
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responsible for the high level of aneuploidy observed in those tumors.  First, a new classifier was 
used, PAM50 (Parker, Mullins et al. 2009) with a Claudin-low identifier (Prat, Parker et al.), that 
stratified tumors to homogeneous groups with strong prognostic value.  SWITCHdna was then 
applied to identify segments belonging to individual tumors before using the subtypes to 
aggregate the copy number profiles seen in Figure 4.1.  This not only showed several regions that 
were identified in previous work (outlined in Chapter 1) but regions that were more well-refined 
as well as not previously seen.  We identified a large list of genes that were found within the 
CNA peaks which we statistically associated to each subtype (seen Appendix IVA), most notably 
those in basal-likes, where 50% of the tumor genome has copy number events.  This high-CNA 
information was used during association of genes to subtypes and identified 3 genes in particular: 
RAD50, RAD17 and RAP80 (UIMC1), with low p-values that belong to the DNA damage 
pathway and associated to TP53 mutation (Table 4.1).  Using this information, knockout cell 
lines were created to emulate these mutations/losses, which showed that loss of these genes lead 
to impaired DNA repair and increased sensitivity to DNA damaging agents.   
In summary, the interlinked duality of biology and bioinformatics has provided an ability 
to look at these problems from several disciplines to arrive at the conclusions provided in this 
work.  This work has shown the benefits of rigorous analysis of genomic data from breast tumors 
at varying levels of granularity: from discovery, to classification, to the creation of new tools that 
can be used by future biologists to build upon.  This has led to the development of two methods, 
LAS and SWITCHdna, to address initial analyses and provide formats and outputs that are easily 
interpreted and can be incorporated with association metrics.  Previous work in breast cancer has 
shown improvements limited by their classification and prognostic ability (i.e. not providing new 
biomarkers or treatment possibilities), leaving underlying etiology and drug-effects under-
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evaluated and not providing insight for therapeutics.  Through these studies, an EGFR-pathway 
signature was identified that may be suggestive of EGFR inhibitor therapy sensitivity, and a 
DNA repair pathway signature/CNA (5q loss) was identified that may be suggestive of 
sensitivity to  PARP-inhibitors and platins (cisplatin/carboplatin).  With this kind of progress, the 
genomic age is now providing biological and clinical insights that should result in improvements 
in patient outcomes. 
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APPENDIX IIA 
Please see “Genes from Cluster #1-3 identified from the 500 SUM102 genes clustered on the 
UNC tumor dataset.”. Now available at:  
http://www.biomedcentral.com/content/supplementary/1471-2164-8-258-s4.doc
APPENDIX IVA 
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APPENDIX IVB 
 
Patients in the UNC337 and NKI295 datasets were ranked ordered by average gene expression values of RAD17 
and RAD50, or gene expression of INPP4B.  The patients were split into 3rds and Kaplan Meier analysis was done 
on the three groups to examine trends in relapse-free survival and overall survival.  P-values determined by log-rank 
test.
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APPENDIX IVC 
Subtype classifications using both the original labels in the Borg dataset concerning copy number defined subtypes, 
versus PAM50 plus Claudin-low gene expression subtypes.  P-value determined by Chi-square approximation. 
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